Document:

<PAGE>

                                                                   EXHIBIT 10.40

CONFIDENTIAL TREATMENT REQUESTED
UNDER 17 C.F.R. (S)(S) 200.80(b) (4), 200.83 AND 240.24b-2

                         MASTER COLLABORATION AGREEMENT

                                    BETWEEN

                              DIVERSA CORPORATION

                                      AND

                            THE DOW CHEMICAL COMPANY
<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
             Article                              Title                                Page
-----------------------------------------------------------------------------------------------------------
        <S>                                <C>                                  <C>
               1                               Definitions                              1
-----------------------------------------------------------------------------------------------------------
               2                                 Grants                                 6
-----------------------------------------------------------------------------------------------------------
               3                           Project Agreements                           8
-----------------------------------------------------------------------------------------------------------
               4                      Royalties, Reports and Payments                   10
-----------------------------------------------------------------------------------------------------------
               5                             Confidentiality                            12
-----------------------------------------------------------------------------------------------------------
               6                               Publication                              13
-----------------------------------------------------------------------------------------------------------
               7                          Intellectual Property                         14
-----------------------------------------------------------------------------------------------------------
               8                            Option to [***]                             18
-----------------------------------------------------------------------------------------------------------
               9                         Term and Disengagement                         18
-----------------------------------------------------------------------------------------------------------
              10                         Product Liability and                          19
                                           Indemnification
-----------------------------------------------------------------------------------------------------------
              11                    Export and Compliance with Laws                     20
-----------------------------------------------------------------------------------------------------------
              12                          Dispute Resolution                            20
-----------------------------------------------------------------------------------------------------------
              13                     Representations and Warranties                     21
-----------------------------------------------------------------------------------------------------------
              14                             Bankruptcy                                 22
-----------------------------------------------------------------------------------------------------------
              15                           Force Majeure                                23
-----------------------------------------------------------------------------------------------------------
              16                      Assignment and Successors                         23
-----------------------------------------------------------------------------------------------------------
              17                              Notice                                    23
-----------------------------------------------------------------------------------------------------------
              18                          Miscellaneous                                 24
-----------------------------------------------------------------------------------------------------------
</TABLE>

<TABLE>
<CAPTION>
                     Exhibits                                               Title
---------------------------------------------------------------------------------------------------------
                 <C>                                    <S>
                          1                                  Confidential Disclosure Agreement
---------------------------------------------------------------------------------------------------------
                          2                                                [***]
---------------------------------------------------------------------------------------------------------
</TABLE>
-----------------
* CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                                       Project Agreements*
<TABLE>
<CAPTION>

                Appendix                                               Title
---------------------------------------------------------------------------------------------------------
       <S>                                      <C>
                  A-1                             Schedule of DIVERSA Patent Rights under the Project
                                                                    Agreement
---------------------------------------------------------------------------------------------------------
                  A-2                              Schedule of DIVERSA Patent Rights predate this MCA
                                                     and Project Agreement but needed for Licensed
                                                                      Products
---------------------------------------------------------------------------------------------------------
                  B-1                              Schedule of TDCC Patent Rights under the Project
                                                                     Agreements
---------------------------------------------------------------------------------------------------------
                  B-2                              Schedule of TDCC Patent Rights that predate this
                                                  MCA and Project Agreement, but needed for Licensed
                                                                       Product
---------------------------------------------------------------------------------------------------------
                   C                                  List of Licensed Enzyme and Project Field
---------------------------------------------------------------------------------------------------------
                  D-1                                            MTA for an Institute
---------------------------------------------------------------------------------------------------------
                  D-2                                        MTA for a Toll Manufacturer
---------------------------------------------------------------------------------------------------------
                  D-3                                            MTA for a Customer
---------------------------------------------------------------------------------------------------------
                  E                                                     [***]
---------------------------------------------------------------------------------------------------------
                  F                                Schedule of Licensed Patents from DIVERSA Patent
                                                    Rights for a Licensed Product (subset or all of
                                                                     Appendix A-1)
---------------------------------------------------------------------------------------------------------
</TABLE>

* Will be provided as each Project Agreement is signed
-----------------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       2

<PAGE>

                        MASTER COLLABORATION AGREEMENT

This Agreement ("MCA") is made by and between Diversa Corporation, a corporation
duly formed and existing under the laws of the State of Delaware, having a place
of business at 10665 Sorrento Valley Road, San Diego, CA 92121 (hereinafter
"DIVERSA" or "Party"), and The Dow Chemical Company, a corporation duly formed
and existing under the laws of the State of Delaware, having a place of business
at 2030 Dow Center, Midland, MI 48674 (hereinafter "DOW" or a "Party").

                                R E C I T A L S

A.   DIVERSA has discovered and developed enzymes and has expertise in the
     rearrangement of DNA to produce and discover genes utilizing proprietary
     technologies for the rapid discovery, development and optimization of
     enzymes.

B.   TDCC has a contract manufacturing business for preparing pharmaceutical
     products for the pharmaceutical industry.

C.   TDCC and DIVERSA desire to work together to discover, manufacture, market
     and sell biological enzyme-based chiral products and services for
     pharmaceutical applications.

D.   TDCC and DIVERSA are concurrently with this MCA entering into separate
     Project Agreements in order to perform research together to have DIVERSA
     discover and optimize the function of new genes, and to have TDCC develop
     and maximize processes and products for making chiral products resulting
     therefrom for use in the pharmaceutical marketplace.

E.   DIVERSA represents that it has Patent Rights and Know-How that pertain to
     this MCA.

F.   TDCC is desirous of obtaining, and DIVERSA wishes to grant, a worldwide
     license to sell enzymes discovered or developed by DIVERSA for making
     chiral compounds for the pharmaceutical marketplace.

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and
for other good and valuable consideration, the receipt and sufficiency of which
the Parties hereby acknowledge, the Parties hereby agree as follows:

                            Article 1.  DEFINITIONS

When used in this MCA, the following terms shall have the meanings set out
below, unless the context requires otherwise.  The singular shall be interpreted
as including the plural and vice versa, unless the context clearly indicates
otherwise.

1.1  "Affiliate" means any corporation, firm, limited liability company,
      ---------
     partnership or other entity that is directly or indirectly controlled by a
     Party. Control for this purpose means ownership, directly or through one or
     more affiliated entities, of greater than fifty percent (50%) of the shares
     of stock entitled to vote for the election of directors in the case of a
     corporation, or more than fifty percent (50%) of the equity interests in
     the case of any other type of legal entity, or any other arrangement
     whereby a Party controls or has the
<PAGE>

     right to control the board of directors or equivalent governing body of a
     corporation or other entity.

1.1  "API" means [***].
      ---

1.2  "CDA" means the Confidentiality Agreement between the Parties, effective
      ---
     February 23, 1999 and its amendment effective May 16, 2000.  For ease of
     reference a copy thereof is attached hereto as Exhibit 1.

1.3  "Change of Control" means any of the following transactions involving a
      -----------------
     Third Party:
     a)   a merger or consolidation of either Party which results in the voting
          securities of such Party outstanding immediately prior thereto ceasing
          to represent more than 50% of the combined voting power of the
          surviving entity immediately after such merger or consolidation;
     b)   the sale of all or substantially all of the assets of either Party;
     c)   the sale of substantially all the assets relevant to the Field; or
     d)   any one person (other than the Party, any trustee or other fiduciary
          holding securities under an employee benefit plan of the Party or any
          corporation owned directly or indirectly by the stockholders of the
          Party, in substantially the same proportion as their ownership of
          stock of the Party), together with any of such person's "affiliates"
          or "associates", as such terms are used in the Securities Exchange Act
          of 1934, as amended, becoming beneficial owner of more than 50% of the
          combined voting power of the outstanding securities of a Party or by
          contract or otherwise having the right to control the board or
          directors or equivalent governing body of such Party nor the ability
          to cause the direction of management of such Party.

1.4  "Confidential Information" means all information which the disclosing Party
      ------------------------
     could reasonably expect to be deemed confidential (e.g., TDCC Know-How,
     DIVERSA Know-How, scientific, technical, or non-technical data,
     Intermediates, APIs, business plans, identity of a Sublicensee, financial
     projections, and marketing and sales information) disclosed by one Party to
     the other, whether disclosed or provided in oral, written (including but
     not limited to electronic, facsimile, paper or other means), graphic,
     photographic or any other form, except to the extent that such information:
     a)   as of the date of disclosure is known to the receiving Party as shown
          by written documentation, other than by virtue of a prior confidential
          disclosure from the disclosing Party to the receiving Party;
     b)   as of the date of disclosure is in, or subsequently enters, the public
          domain through no fault or omission of the receiving Party;
     c)   as of the date of disclosure or thereafter is obtained from a Third
          Party free from any obligation of confidentiality; or
     d)   as of the date of disclosure or thereafter is developed by the
          receiving Party independent of the disclosure by the disclosing Party
          as evidenced by written documentation.

     Any information first submitted to the other Party in a non-written form
     must be identified as confidential information at that time, then reduced
     to writing within thirty (30) days, marked as confidential and provided to
     the receiving Party.

1.5  "Controls" or "Controlled" means, with respect to intellectual property,
      --------      ----------
      possession (other than by virtue of this MCA) of the ability to grant
      licenses or sublicenses to the other Party hereto or to its Sublicensee
      without violating the terms of any agreement or other arrangement with any
      Third Party and to the knowledge and belief of the granting Party without
      violating the rights of a Third Party.

--------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       2
<PAGE>

1.6   "Customers" means any entity that is only sold Licensed Enzyme,
       ---------
      Intermediates or API for pharmaceutical applications and is not provided
      process information and is not a Sublicensee.

1.7   "DIVERSA" means Diversa Corporation, having a place of business at San
       -------
      Diego, California.

1.8   "DIVERSA Know-How" means all [***] and any other information of any kind
       ----------------
      (a) which are conceived, discovered or invented during any Project
      Agreement under the terms of this MCA or (b) which have been conceived,
      discovered or invented by DIVERSA prior to this MCA and Controlled solely
      by DIVERSA, which are necessary or appropriate to develop and
      commercialize Licensed Products.

1.9   "DIVERSA Intellectual Property" means DIVERSA Patent Rights and DIVERSA
       -----------------------------
      Know-How.

1.10  "DIVERSA Patent Rights" means (a) all patents and patent applications
       ---------------------
      which are conceived of during the term of the Project Agreements, and
      which are necessary for [***]. If such patent rights arise they shall be
      listed on Appendix A-1, attached to each Project Agreement and made a part
      thereof; (b) the patents and patent applications listed on Appendix A-2,
      attached thereto and made a part thereof, are patent rights of DIVERSA
      that predate this MCA but which patent rights are necessary for [***]; and
      (c) any divisions, continuations, continuations-in-part, reissues,
      reexaminations, extensions or other governmental actions which extend any
      of the subject matter of the patent applications or patents in (a) or (b)
      above, and any substitutions, confirmations, patents-of-addition,
      registrations or revalidations of any of the foregoing, in each case,
                                                              ------------
      which are Controlled by DIVERSA during the term of the Project Agreements
      and which are necessary for [***]. All patents and patent applications
      subject to this definition are listed on Appendix A or will be included on
      Appendix A attached to each Project Agreement by the expiration of the
      research term of each Project Agreement.

1.11  "Effective Date" means September 1, 2000.
       --------------

1.12  "Enzyme" means [***].
       ------

1.13  "Field" means the discovery, development, manufacture, marketing and sale
       -----
      of Licensed Products, [***]and services for [***] used in [***].

1.14  "FTE" means the equivalent of one full year of work on a full time basis
       ---
      by a DIVERSA scientist or other professional possessing the skills and
      experience necessary to carry out the Work Plans under a Project
      Agreement. It is understood that a full year for any given scientist or
      professional may not be required so that partial years for any given
      person could result. FTE needs shall form a part of the Staffing Level of
      each Project Agreement.

1.15  "Intermediate" means [***].
       ------------

1.16  "Joint Patent Rights" means Patent Rights that are developed or invented
       -------------------
      by both Parties in the course of the performance of any Project Agreement.
      If the item developed or invented results in a patentable invention, such
      invention is jointly developed if both Parties' employees or consultants
      are considered inventors under 35 U.S.C. et seq. and

-----------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       3
<PAGE>

      37 C.F.R. et seq., as interpreted by the U. S. Patent and Trademark Office
      and the United States Federal Courts.

1.17  "License" means the license agreement(s) attached to each Project
       -------
      Agreement as Exhibit 4 thereto.

1.18  "Licensed Enzyme" means any Enzyme, which is commercialized under this
       ---------------
      MCA, for use in a Project Field. The Licensed Enzyme and Project Field
      shall be designated on each Project Agreement and listed in Appendix C
      attached thereto and made a part thereof.

1.19  "Licensed Product" means (a) [***] or (b) [***].
       ----------------

1.20  "Licensed Patents" means DIVERSA Patent Rights that are necessary to have
       ----------------
      the freedom to practice Licensed Products and are indicated on Appendix F
      attached to each Project Agreement and made a part thereof. It is expected
      that such Licensed Patents will be all or a subset of the DIVERSA Patent
      Rights listed in Appendix A with each Project Agreement.

1.21  "MTA" means a material transfer agreement for exchange of any Licensed
       ---
      Enzyme (with or without DIVERSA Know-How or TDCC Know-How) to any Third
      Party by DIVERSA or TDCC, a copy of which is attached hereto as Appendix D
      for transfer between TDCC or DIVERSA and a Third Party.  Appendix D-1 for
      an Institute; Appendix D-2 for a Toll Manufacturer; and Appendix D-3 for a
      Customer.  Any MTA shall be used only under the terms of a Project
      Agreement.  Any transfer of Enzymes or Licensed Enzymes between TDCC and
      DIVERSA shall be deemed Confidential Information (provided under the
      confidentiality provisions of this MCA) and not require an MTA.

1.22  "Patent Rights" means DIVERSA Patent Rights, TDCC Patent Rights and Joint
       -------------
      Patent Rights.

1.23  "Project Agreements" means each individually executed agreement detailing
       ------------------
      a specific research objective in the Project Field, budget with FTE
      requirements, and Work Plan, that is attached hereto and made a part
      hereof and incorporating the terms of this MCA that are referenced
      therein. One Project Agreement shall be signed within 60 days of this MCA;
      and other Project Agreements may be appended at any time during the Term
      of this MCA.

1.24  "Project Field" means a [***].
       -------------

1.25  "Purpose" means having the Parties provide an integrated, full service
       -------
      offering of [***] to Customers.  This service and Licensed Products may be
      offered as early as [***].  Specifically excluded from this Purpose is the
      identification of [***].

1.26  "Signature Date" means the date of last signature to this MCA.
       --------------

1.27  "Staffing Level" shall have the meaning set forth in each Project
       --------------
      Agreement.

1.28  "Sublicensee" means a Third Party that has a license agreement with TDCC
       -----------
      in the Project Field for Licensed Products.

1.29  "TDCC" means The Dow Chemical Company, having a place of business at
       ----
      Midland, Michigan.

-----------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       4
<PAGE>

1.30  "TDCC Intellectual Property" means TDCC Patent Rights and TDCC Know-How.
       --------------------------

1.31  "TDCC Know-How" means all TDCC Confidential Information [***] and other
       -------------
      information of any kind (a) which are conceived, discovered or invented
      during any Project Agreement under the terms of this MCA or (b) which have
      been conceived, discovered or invented by TDCC prior to this MCA and
      Controlled solely by TDCC, which are necessary or appropriate to develop
      and commercialize Licensed Products.

1.32  "TDCC Patent Rights" means (a) all patents and patent applications which
       ------------------
      are conceived of during the term of the Project Agreements, and which are
      necessary for TDCC to make, have made, use, import, sublicense, export,
      sell or have sold the Licensed Products. If such patent rights arise they
      shall be listed on Appendix B-1, attached to each Project Agreement and
      made a part thereof; (b) the patents and patent applications listed on
      Appendix B-2, attached thereto and made a part thereof, are patent rights
      of TDCC that predate this MCA but which patent rights are necessary for
      TDCC to make, have made, use, sublicense, import, export, sell or have
      sold the Licensed Products; and (c) any divisions, continuations,
      continuations-in-part, reissues, reexaminations, extensions or other
      governmental actions which extend any of the subject matter of the patent
      applications or patents in (a) or (b) above, and any substitutions,
      confirmations, patents-of-addition, registrations or revalidations of any
      of the foregoing, in each case, which are Controlled by TDCC during the
                        ------------
      term of the Project Agreements and which are necessary for TDCC to make,
      have made, use, sublicense, import, export, sell or have sold the Licensed
      Products. All patents and patent applications subject to this definition
      are listed on Appendix B or will be included on Appendix B attached to
      each Project Agreement by the expiration of the research term of each
      Project Agreement.

1.33  "Term" means the duration of this MCA which is [***] from the Effective
       ----
      Date, unless extended by mutual written agreement.

1.34  "Territory" means the world.
       ---------

1.35  "Third Party" means any party who is not a Party, or an Affiliate.
       -----------

1.36  "Work Plans" mean the written research plans defining the activities to be
       ----------
      carried out under each Project Agreement, and the budget, for each project
      within the Project Field, as more specifically detailed in Appendix E
      attached thereto and made a part thereof, which may be modified from time
      to time by written amendment.

                              Article 2:  GRANTS

2.1  Exclusive Grants -
     -----------------
     2.1.1  The Parties agree to a [***] exclusive marketing relationship
            starting from the Effective Date for Licensed Enzymes and Licensed
            Products in the Territory for the Field and in accordance with the
            Purpose.

     2.1.2  The Licensed Enzyme and Licensed Product for a specific marketplace
            need of a Customer or Sublicensee shall be the subject of separate
            Project Agreements, that are attached hereto and made a part hereof,
            as described in Article 3. The Licensed Enzyme and Licensed Product
            under each Project Agreement is exclusive to TDCC and in accord with
            the terms of this MCA and the terms of each Project Agreement.

---------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       5
<PAGE>

2.2  Reservations -
     ------------
     2.2.1  [***] - To achieve the Purpose of this MCA, the Parties agree [***]:
            (a)  [***]
            (b)  [***]
            (c)  [***].

     2.2.2  Exercise of [***]- The Party presented with [***].
            ----------------------------------

     2.2.3  Interactions with Third Parties - Both Parties may individually or
            -------------------------------
            with a Third Party pursue any project opportunity outside the Field.
            These project opportunities shall not be subject to [***]. Within
            the Field, each Party may interact with any Third Party in accord
            with Sections 2.1 and 2.2.

2.3  Nonexclusive Grants - Unless a Project Agreement has been signed (with
     -------------------
     payment made or work begun, including Work Plans), either Party shall be
     free to develop and market its services in the Field to Customers and Third
     Parties during the term of this MCA. However, [***].

2.4  Roles and Responsibilities -
     --------------------------
     2.4.1  DIVERSA - DIVERSA shall be responsible for [***].
            -------

     2.4.2  TDCC - TDCC shall [***].
            ----

     2.4.3  Licensed Enzyme Manufacture - Where, prior to the signature date of
            ---------------------------
            a Project Agreement, DIVERSA has [***] then [***].

     2.4.4  When either Party interacts with a Third Party with respect to
            opportunities within the Field, that interacting Party shall use its
            commercially reasonable efforts to negotiate confidentiality terms
            that permit the other Party to be included in the discussions and/or
            to provide the Confidential Information of the other Party. The
            other Party shall be notified as promptly as possible of these
            discussions, including the identity of the Third Party, the specific
            Project Field, and the Confidential Information disclosed, in each
            case if such information is capable of being disclosed without
            breaching any confidentiality agreement. If samples of Licensed
            Enzymes are concerned then an MTA shall be required.

2.5  Litigation - Each Party shall be responsible for defending its own Patent
     ----------
     Rights.  Joint Patent Rights defense shall be discussed as to the
     respective interests involved.

2.6  Product Liability - The Customer or Sublicensee shall be responsible for
     -----------------
     all liability of the final drug product or its use of the Intermediate, API
     or Licensed Enzyme.

                        Article 3.  PROJECT AGREEMENTS

3.1  [***] Obligation for Project Agreements - Before any project by either
          ----------------------------------
     Party for the Purpose in the Field can be undertaken [***], the other Party
     must [***].  This [***] shall be in accordance with Section 2.2.  If that
     Party does desire to participate, then, a Project Agreement shall be
     negotiated, using each Party's good faith efforts.

------------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       6
<PAGE>

3.2  Terms Required for Each Project Agreement - Each Project Agreement,
     -----------------------------------------
     independently, shall contain its own budget (including FTEs funded [***]),
     Patent Rights appendices from each Party, Work Plans, terms regarding
     TDCC's diligence obligation to pursue commercialization, and reference to
     this MCA for terms to be maintained. Any royalties or other payments due
     shall be negotiated separately for each Project Agreement.

3.3  Improvements during a Project Agreement - Any Licensed Enzyme improvements
     ---------------------------------------
     made by DIVERSA in the Project Field for the Project Agreement during the
     term of either this MCA or the Project Agreement shall [***].

3.4  MCA Terms Carried to each Project Agreement - The Parties agree to be bound
     -------------------------------------------
     by and incorporate into each Project Agreement the terms of this MCA.

3.5  Exclusive Grant Provided Under Each Project Agreement - For each Project
     -----------------------------------------------------
     Agreement, the Licensed Product shall be granted exclusively to TDCC for
     the Project Field subject to the terms and conditions of the Project
     Agreement and this MCA. DIVERSA's Intellectual Property shall form a
     schedule(s) for this exclusive grant. Notwithstanding anything to the
     contrary contained herein, DIVERSA shall not be required to license, or
     hold harmless TDCC against infringements of, DIVERSA Intellectual Property
     that is not legally required for TDCC to carry out its roles and
     responsibilities hereunder (as set forth in Section 2.4.2) without
     infringing DIVERSA Intellectual Property (e.g., [***], TDCC will be
     required to negotiate with DIVERSA for an appropriate license or hold
     harmless as part of the applicable Project Agreement). Specific grants for
     each Project Agreement will be included in that document, which grants
     shall control over this MCA for that Project Field.

3.6  Term of Each Project Agreement - The term of each grant of the exclusive
     ------------------------------
     license to TDCC in accord with Section 3.5 for any Licensed Product shall
     be the last to expire of the Patent Rights, including any extensions,
     unless terminated earlier by TDCC or its Sublicensee.

3.7  Indemnity by DIVERSA - DIVERSA shall indemnify and hold TDCC, its agents,
     --------------------
     directors, officers, employees and Affiliates harmless from and against any
     and all liabilities, claims, demands, damages, costs, expenses or money
     judgments (including reasonable attorneys' fees and expenses) incurred by
     or rendered against any of them for personal injury, sickness, disease or
     death or property damage which directly arise out of:
     (a)  the intentional misconduct or negligence of DIVERSA; or
     (b)  the breach by DIVERSA of its representations, warranties or covenants
          contained in this MCA or any Project Agreement; or
     (c)  any activity carried out with Enzyme and Licensed Enzyme by DIVERSA
          other than through TDCC and its Affiliates under this MCA or Project
          Agreement; provided, however, that TDCC shall give DIVERSA notice in
          writing in accord with Article 17 as soon as practicable of any such
          claim or lawsuit and shall permit DIVERSA to undertake the defense
          thereof (including the right to settle the claim solely for monetary
          consideration) at DIVERSA's expense. However,
          (i)  TDCC will cooperate in such defense by providing access to
               witnesses and evidence available to it.  TDCC shall have the
               right to participate in any defense to the extent that in its
               judgment, TDCC may be prejudiced thereby; and
          (ii) in any claim or suit in which TDCC seeks indemnification by
               DIVERSA, TDCC shall not settle, offer to settle or admit
               liability or damages in any such claim or suit without the prior
               written consent of DIVERSA.

----------------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       7
<PAGE>

3.8  Indemnity by TDCC - TDCC shall defend, indemnify and hold DIVERSA and its
     -----------------
     Affiliates, and their respective agents, directors, officers, and employees
     harmless from and against any and all losses, liabilities, claims, demands,
     damages, costs, expenses or money judgments (including reasonable
     attorneys' fees and expenses) incurred by or rendered against any of them
     for personal injury, sickness, disease or death or property damage which
     arise out of
     (i)    the development, manufacturing, testing, handling, storage, use,
            promotion, sale or distribution of Licensed Products by TDCC or its
            Affiliates, except for those instances for which DIVERSA and not
            TDCC performs any of these functions; or
     (ii)   the breach by TDCC of any of its representations, warranties or
            covenants contained in this MCA or any Project Agreement; or
     (iii)  the intentional misconduct or gross negligence of TDCC;

          provided, however, that DIVERSA shall give TDCC notice in writing in
          accord with Article 17 as soon as practicable of any such claim or
          lawsuit and shall permit TDCC to undertake the defense thereof at
          TDCC's expense.  However,
          (i)   DIVERSA will cooperate in such defense by providing access to
                witnesses and evidence available to it. DIVERSA shall have the
                right to participate in any defense to the extent that in its
                judgment, DIVERSA may be prejudiced thereby; and
          (ii)  In any claim or suit in which DIVERSA seeks indemnification by
                TDCC, DIVERSA shall not settle, offer to settle or admit
                liability or damages in any such claim or suit without the prior
                written consent of TDCC.

3.9   [***] - The Parties agree [***].

3.10  Customer MTA - Any transfer of Confidential Information belonging to the
      ------------
      disclosing Party which the receiving Party desires to provide to a
      Customer must be done under an appropriate MTA of Appendix D. This
      requirement includes samples, know-how, Enzymes, and any other
      Confidential Information. A copy of the signed MTA must be supplied by the
      Party that is disclosing the Confidential Information to the Party that
      owns the Confidential Information.

                  Article 4.  ROYALTIES, REPORTS AND PAYMENTS

4.1  Annual Payment - TDCC shall pay DIVERSA an annual fee for the first year,
     --------------
     within thirty (30) days of the Signature Date, of [***] and as an annual
     fee thereafter by the anniversary of the Effective Date thereafter,
     beginning with 2001, of [***] per year for all exclusivity rights under
     Project Agreements to retain their exclusivity as well as for retaining the
     nonexclusive rights in the Field under this MCA. If TDCC terminates this
     MCA then each Project Agreement shall be maintained on its terms, but the
     rights to the Field are terminated.

4.2  FTE Payments - TDCC shall pay DIVERSA under each Project Agreement for the
     ------------
     FTE budget, quarterly in advance, and in the amounts as negotiated and set
     forth in the applicable Project Agreement. [***].

4.3  Milestone Payments - TDCC shall pay DIVERSA on the first occurrence for
     ------------------
     each Project Agreement of the following events:
     -----

------------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       8
<PAGE>

     (a)  [***]; or
                 --

     (b)  [***].

4.4  Earned Royalty - To be paid for each Project Agreement - TDCC shall pay
     --------------                  ----
     DIVERSA [***].

4.5  [***]

4.6  Enzyme Library Fee - TDCC shall have access to DIVERSA's enzyme
     ------------------
     subscription library for [***] per year for a [***] subscription. A
     separate agreement, having at least the standard conditions offered to all
     subscribers, shall be provided.

4.7  DIVERSA Payment to TDCC - DIVERSA shall pay TDCC for [***].
     -----------------------

4.8  Records -
     -------
     4.8.1  TDCC and DIVERSA shall keep accurate records of all operations
            affecting payments under this MCA, and shall permit the other
            Party's duly authorized agent, which is not unreasonably
            objectionable to the Party to inspect all such records during normal
            business hours throughout the term of this MCA and for [***] after
            termination.

     4.8.2  TDCC shall keep accurate records of all operations affecting
            payments under each Project Agreement, and shall permit DIVERSA's
            duly authorized agent, which is not unreasonably objectionable to
            TDCC, to inspect all such records during normal business hours
            throughout the term of each Project Agreement and for [***]
            thereafter.

4.9  Tax Issues - Any stamp duties or taxes due or paid on behalf of one Party
     ----------
     by the other Party shall be rectified at the end of each calendar year in
     the final accounting for that year. [***].

4.10  Payment Addresses - All payments due under Article 4 of this MCA or any
      -----------------
      Project Agreement shall be made by bank wire transfer in immediately
      available funds to:

      TDCC at:
           [***]

      All payment reports due under the MCA shall reference TDCC's agreement
      number [***], indicate the amount of payment with the date payment was
      made and an itemized listing and be sent to:

          The Dow Chemical Company
          Royalty Accounting
          2020 Dow Center
          Midland, MI 48674
          USA

     DIVERSA at:
       [***]

4.11  Late Payments - In the event that the due date of any payment subject to
      -------------
      this Article 4 (which shall only be deemed late if unpaid after forty-five
      days from its due date) is a Saturday, Sunday or holiday, such payment may
      be paid on the following business day.

-------------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       9
<PAGE>

     Any late payments shall bear interest to the extent permitted by applicable
     law at the prime rate (as reported by CitiBank, New York, NY or its
     successor), on the date such payment is due plus an additional [***],
     calculated on the number of days such payment is delinquent. The rights
     provided in this Section 4.9 shall in no way limit any other remedies
     available to the Parties hereunder. The defaulting Party may cure in accord
     with Section 9.3.

                          Article 5.  CONFIDENTIALITY

5.1  Effort - All Confidential Information shall not be disclosed by the
     ------
     recipient Party to any Third Party without the prior written approval of
     the disclosing Party.  Each Party shall use good faith efforts to retain in
     confidence and not disclose to any Third Party each other's Confidential
     Information disclosed pursuant to the terms of this MCA or under the terms
     of any Project Agreement.  Such "good faith efforts" shall mean the same
     degree of care, but no less than a reasonable degree of care, as the
     receiving Party uses to protect its own Confidential Information of a like
     nature.  All Confidential Information initially received in a non-written
     form shall be reduced to writing within thirty (30) days by the disclosing
     Party and such writing provided to the receiving Party.  The receiving
     Party shall not be obligated if such writing is not received timely.
     Exceptions to this Section 5.1 are stated in Sections 5.4 and 5.5.

5.2  CDA - The terms of the CDA shall remain in effect with regard to all
     ---
     activities between the Parties for the Field prior to the Effective Date.
     After the Effective Date the terms of this MCA shall control disclosure
     between the Parties for the Field.  Should any disclosure occur between the
     Parties that falls outside the Field, then only the CDA terms control.

5.3  Governmental Regulatory Submissions - If the MCA or any Project Agreement
     -----------------------------------
     must be provided to the public or a governmental agency, then redaction of
     as many terms as possible from this MCA and Project Agreements, with
     notification to the other Party, is required by the disclosing Party.

5.4  Exception for MCA Purpose - Notwithstanding the provisions of Section 5.1,
     -------------------------
     each Party may use Confidential Information of the other Party only to the
     extent required to accomplish the Purpose of this MCA. Because of the
     Purpose of this collaboration, the Parties agree that in order to
     sublicense or to sell Licensed Products in the Project Field, it may be
     necessary to disclose, under a confidentiality agreement (with terms at
     least as restrictive as those contained herein) and/or MTA, to a Third
     Party some Confidential Information of the Parties. However, before any
     such Confidential Information or MTA is signed or transferred with the non-
     disclosing Party's Confidential Information, the disclosing Party must
     determine whether the Third Party meets [***]. If it does, then no
     disclosure may be made of such Confidential Information without the non-
     disclosing Party's written consent. If no, then the confidentiality and MTA
     mentioned hereinabove must be used. The Party whose Confidential
     Information is being so disclosed shall be notified and the identity of the
     Third Party provided. Each Party hereby agrees to such disclosure to a
     Third Party for the Project Field for the Purpose of this collaboration to
     enable marking of the Licensed Products.

5.5  Exception for Legal Reasons - Notwithstanding the provisions of Section
     ---------------------------
     5.1, if the receiving Party becomes legally compelled to disclose any of
     the disclosing Party's Confidential Information, the receiving Party shall
     promptly advise the disclosing Party of such required disclosure in order
     that the disclosing Party may seek a protective order confidential
     treatment or such other remedy as the disclosing Party may consider

---------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       10
<PAGE>

     appropriate in the circumstances.  The receiving Party shall disclose only
     that portion of the Confidential Information that it is legally required to
     disclose. Such a disclosure shall not release the receiving Party with
     respect to the Confidential Information so disclosed except to the extent
     of permitting the required disclosure.

5.6  Disclosure to Affiliates, Contractors - Provided the information is not
     -------------------------------------
     disclosed to a Third Party who possesses [***] of the non-disclosing Party,
     TDCC or DIVERSA may disclose Confidential Information to their Affiliates,
     Sublicensees, consultants, contractors (parties under contract with TDCC
     for the custom manufacturing or shipping of Licensed Products or obtention
     of registration in the Territory), as may be necessary to exercise the
     rights granted hereunder and to register and prepare for commercialization
     of Licensed Products, and to commercialize Licensed Products under this
     MCA, under conditions of confidentiality at least as stringent as those set
     out in Article 5.

5.7  Survival of Confidentiality - Termination of this MCA for any reason shall
     ---------------------------
     not relieve the Parties of their obligations under Article 5.  The
     provisions of Article 5 shall survive termination of this MCA for [***].

                            Article 6.  PUBLICATION

6.1  Rights to Publish in Technical Journals or at Seminars - Each Party and its
     ------------------------------------------------------
     employees shall have the right to publish or present the results of
     Licensed Enzymes in the Fields under this MCA, provided such publication or
     presentation does not disclose Confidential Information of the other Party,
     and further provided that contributions by the other Party to such results
     are acknowledged.  If the publication is disclosing Enzymes, then the prior
     mutual consent of the Parties is required.  If consent is not given, no
     publication may occur.  All publication requests will be reviewed with
     consideration of the Purpose and the protection of Patent Rights.  The
     publishing/presenting Party will submit for review a copy of the proposed
     publication (including abstracts, or presentation to a journal, editor,
     meeting, seminar or other Third Party) resulting from discovery or use of
     the Licensed Enzymes under this MCA to the other Parties at least [***]
     prior to submission for publication, and if no response is received within
     [***] of the date submitted to the other Party, it may be conclusively
     presumed that the publication may proceed without delay.  Notwithstanding
     this paragraph, if a Sublicensee or Customer exists for a Project Agreement
     that would be affected by this publication, then that Sublicensee or
     Customer must also consent in writing to this publication.

6.2  Permitted Delay - If a Party determines that the proposed publication
     ---------------
     contains patentable subject matter which requires protection, that Party
     may require the delay of the publication for a period of time not to exceed
     [***] (or mutually agreed upon time) for the purpose of allowing the
     pursuit of such protection.  If the Sublicensee or Customer objects to the
     publication that impacts its Project Agreement or license, such publication
     shall not occur until such consent is given by that Customer or
     Sublicensee.

                   Article 7.  INTELLECTUAL PROPERTY RIGHTS

7.1  Inventorship - Inventorship on Patent Rights shall be determined using the
     ------------
     U.S. Patent laws (35 U.S.C et seq.) and regulations (37 C.F.R. et seq.) and
     U.S. Federal Court decisions. Because inventorship is a difficult area of
     the law, the Parties agree to use their good faith efforts to resolve any
     disputes. Should that effort fail, then a mutually agreed upon outside
     patent counsel shall make the determination of inventorship and the

-----------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       11
<PAGE>

     Parties shall share equally the costs of that counsel. If Joint Patent
     Rights occur each claim shall have its inventorship determined using this
     same procedure.

7.2  Ownership and Right to Use -
     --------------------------
     7.2.1  The first determining factor for ownership of any Patent Rights
            shall be which Party is the assignee of the patent or patent
            application. For Joint Patent Rights, and contrary to U.S. Patent
            laws and court decisions and any laws of other countries, the
            assignee of each claim shall determine ownership of that claim and
            shall be the determining factor for the right of each Party to
            practice each claim.

     7.2.2  Each Party shall have a freedom from suit under its Patent Rights
            granted by the other Party to perform its obligations for each
            Project Agreement under its Work Plans. No Party may use the
            Intellectual Property Rights of the other Party for any purpose
            other than to perform its obligations under the Work Plans. All
            rights to use the other Party's Patent Rights or Know-How cease when
            that particular Project Agreement terminates or is completed.

     7.2.3  Notwithstanding the termination or completion of the Project
            Agreement, if there is a Licensed Product resulting from a Project
            Agreement and such Licensed Product is desired by a Customer or
            Sublicensee in the Project Field, then to meet the Purpose those
            Patent Rights for the Licensed Product may be granted by agreement
            (including by label license) to that Customer or licensed to that
            Sublicensee and shall not terminate until the respective agreement
            or license is terminated or expires or the Patent Rights expire.

     7.2.4  To permit the Purpose of the Parties for Licensed Products with
            Sublicensees and Customers, the right to practice various claims and
            Patent Rights (including required DIVERSA Know-How) shall be
            accomplished by a license to TDCC as stated in the attached [***].
            This Chart shall only serve to clarify [***]. All Patent Rights to
            each indicated license shall be granted for each Project Agreement
            by its own attached Patent Rights schedule and all payments for the
            license shall be as stated in Article 4, unless modified in the
            respective Project Agreement. Each license shall be limited to the
            specific Licensed Product for the Project Field.

7.3  Prosecution -
     -----------
     7.3.1  DIVERSA to Maintain DIVERSA Patent Rights - DIVERSA shall have the
            -----------------------------------------
            obligation and be responsible, at its own cost and expense, for
            prosecuting the patent applications in DIVERSA Patent Rights and for
            maintaining, and where possible extending, those DIVERSA Patent
            Rights for the term of each Project Agreement to which those rights
            pertain.

     7.3.2  TDCC to Maintain TDCC Patent Rights - TDCC shall have the obligation
            -----------------------------------
            and be responsible, at its own cost and expense, for prosecuting the
            patent applications in TDCC Patent Rights and for maintaining, and
            where possible extending, those TDCC Patent Rights for the term of
            each Project Agreement to which those rights pertain.

     7.3.3  Maintaining Joint Patent Rights - The Parties shall mutually try to
            -------------------------------
            agree which Party shall maintain any Joint Patent Rights. One Party
            shall have the obligation and be responsible, at its own cost and
            expense, for prosecuting the patent applications in Joint Patent
            Rights, while consulting with the other Party with respect to its
            claims, and for maintaining, and where possible extending, those

--------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       12
<PAGE>

            Joint Patent Rights for the term of each Project Agreement to which
            those rights pertain. If the Parties cannot agree which of them
            should maintain any particular Joint Patent Right, then they shall
            agree on an acceptable outside counsel and each pay one-half of
            those costs.

     7.3.4  Notice of Patent Lapse of Patent Rights - DIVERSA shall promptly
            ----------------------------------------
            advise TDCC of the grant, lapse, nullification, revocation,
            surrender, or invalidation of any of DIVERSA Patent Rights and Joint
            Patent Rights, at least in advance of any abandonment to enable TDCC
            to assume that prosecution, at TDCC's expense, should TDCC not agree
            to such abandonment.

7.4  Validity, Non-Infringement - DIVERSA does not warrant that the manufacture,
     --------------------------
     use and sale of Licensed Enzymes do not fall within the scope of Third
     Party patents or the intellectual property rights of a Third Party.
     However, [***].

7.5  Disclaimer of Warranties as to Patent Rights - Other than as stated in
     --------------------------------------------
     Section 7.3, DIVERSA makes no representation that the inventions covered in
     any DIVERSA Patent Rights are patentable or that the DIVERSA Patent Rights
     are or will be valid or enforceable, nor does DIVERSA warrant or represent
     that the exercise of the rights licensed hereunder is free of infringement
     of patent rights of Third Parties.

7.6  Hold Harmless - DIVERSA agrees to hold TDCC harmless for patent
     -------------
     infringement under any DIVERSA patents or patents licensed to TDCC which
     may be otherwise infringed by TDCC's performance under this MCA or any
     Project Agreement so long as this MCA or the relevant Project Agreement is
     in effect and is not terminated.

7.7  Cooperation - DIVERSA and TDCC shall use good faith efforts to cooperate
     -----------
     with respect to any issues that concern Patent Rights and the development
     of the Licensed Products under this MCA or Project Agreement. [***].

7.7  Third Party Infringement Claims -
     -------------------------------
     7.7.1  Notice of Claim - In the event that TDCC receives a written notice
            ---------------
            of an allegation of possible patent infringement from a Third Party
            or determines that there is such possible infringement based on the
            use of an Enzyme or Licensed Enzyme, TDCC shall notify DIVERSA in
            writing and [***].

     7.7.2  Defense of Third Party Patent Claims - If a claim is brought by a
            ------------------------------------
            Third Party that the manufacture, use or the sale of a Licensed
            Enzyme or its use in Licensed Products in the Territory (regardless
            of use) infringes a patent of such Third Party, TDCC will give
            prompt written notice to DIVERSA of such claim if it concerns
            DIVERSA Patent Rights. The Parties shall confer in accord with
            Section 7.7.3.

     7.7.3  Mutual Decisions - From the Effective Date and using their good
            ----------------
            faith efforts, DIVERSA and TDCC shall discuss any claim or suit
            brought by a Third Party for patent infringement and mutually
            evaluate whether that Third Party's patent is infringed by the
            manufacture, use or sale of any Licensed Enzyme covered in DIVERSA
            Patent Rights by TDCC or its Affiliates or Sublicensees in the
            Territory. Specifically, DIVERSA and TDCC shall mutually try to
            agree on:
            (a)  the strategy for such suit or claim, e.g. whether to negotiate
                 a settlement, sue or withdraw selling the Licensed Enzyme or
                 Licensed Product from the country in the Territory in which
                 infringement is claimed;

--------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       13
<PAGE>

            (b)  the basis to be determined for sharing the costs of litigation,
                 damages awarded, and royalty to be paid to the Third Party ;

            (c)  which Party should conduct the defense or if both DIVERSA and
                 TDCC should jointly defend; and the consequences of such
                 decisions.

     7.7.4  Third Party [***] - TDCC shall use its good faith efforts to [***].
            ------------
            As of the Effective Date for the present Project Agreements for use
            of Licensed Enzyme designation for Licensed Products, [***].

7.8  Patent Enforcement & Litigation -
     -------------------------------
     7.8.1  Enforcement -
            -----------

          7.8.1.1  If either Party learns of any infringement of DIVERSA Patent
                   Rights by a Third Party, it shall promptly notify the other
                   Party.

          7.8.1.2  If the possible infringement concerns a Licensed Enzyme that
                   is competing with TDCC, then DIVERSA shall [***]. DIVERSA
                   will bear the costs and shall be entitled to any recovery
                   obtained from such litigation, settlement or compromise
                   thereof. If DIVERSA elects not to take action for such
                   infringement, then TDCC may do so at TDCC's expense and shall
                   [***].

     7.8.2  Settlement - Any settlement of an infringement suit, whether brought
            ----------
            by TDCC or by DIVERSA, shall be subject to the consent of both
            Parties, which consent shall not be unreasonably withheld.  [***].

     7.8.3  Cooperation - Each Party shall cooperate with the other Party to the
            -----------
            extent reasonably requested in any legal action:

            (a)  related to this MCA or any Project Agreement brought by a Third
                 Party against one Party; or

            (b)  related to this MCA or any Project Agreement brought by a Third
                 Party against both Parties; or

            (c)  taken against a Third Party by either Party regarding DIVERSA
                 Patent Rights in the Field in the Territory, and each Party
                 shall have the right to participate in any defense, compromise
                 or settlement to the extent that, in its judgment, it may be
                 prejudiced thereby.

7.9  Marking -
     -------
     7.9.1  TDCC agrees to mark, where required by law or desired for notice,
            all Licensed Enzymes or Licensed Products sold by it to a Third
            Party under this MCA, including under any sold that result under
            Project Agreements, with the word "Patent" or "Patents" and the
            number or numbers of the Licensed Patents applicable thereto.

     7.9.2  TDCC agrees (a) to mark any Intermediate or API, that [***] and (b)
            to respond to any request for disclosure under 35 U.S.C.
            (S)287(b)(4)(B) by notifying DIVERSA of the request for disclosure,
            if the Licensed Process Patent is owned by DIVERSA.

-------------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       14
<PAGE>

     7.9.3  This marking requirement may be modified in sublicense agreements,
            provided that other adequate notice for damages is provided and any
            legal requirements are met.

7.10  Misuse - TDCC shall use its reasonable best efforts to avoid any patent
      ------
      misuse,[***].

7.11  Multipatent Issues - The Parties agree that identical Patent Rights,
      ------------------
      DIVERSA Patent Rights, TDCC Patent Rights, Joint Patent Rights or a
      combination of such Patent Rights may be required for each Project
      Agreement and that each Project Agreement may differ in the Patent Rights
      required as each project will vary within the Field for the Purpose.

                          Article 8.  OPTION TO [***]

8.1  [***].

8.2  [***].

8.3  [***].

                      Article 9.  TERM AND DISENGAGEMENT

9.1  Term -
     ----
     9.1.1  This MCA shall be effective for [***] from the Effective Date,
            unless otherwise terminated earlier under Section 9.2. The Parties
            may by mutual written consent extend this term.

     9.1.2  The term of this MCA is independent of the Project Agreements. Thus
            each Project Agreement may continue for the term of its respective
            Intellectual Property even if this MCA is terminated earlier.

9.2  Termination -
     -----------
     9.2.1  By a Party - Either Party may terminate this MCA on [***] written
            ----------
            notice, in accordance with Article 17, to the other Party.

     9.2.2  By DIVERSA - If TDCC fails to pay any payments when due under
            ----------
            Article 4 (after notice of default and opportunity to cure), then
            DIVERSA may terminate this MCA in accord with Section 9.3.

     9.2.3  By TDCC - If DIVERSA fails to pay any payments when due under
            --------
            Section 4.7 (after notice of default and opportunity to cure), then
            TDCC may terminate this MCA in accord with Section 9.3.

     9.2.4  Change of Control - TDCC shall have the right to immediately
            -----------------
            terminate this MCA and any or all Project Agreements upon a Change
            of Control of DIVERSA.

     9.2.5  Effect of Termination - Project Agreements that have been signed and
            ----------------------
            funded at the time of termination of this MCA shall continue
            according to their terms and be exclusive grants for their Licensed
            Products or described Project Field.

     9.2.6  Project Agreement - Either Party shall have the right to immediately
            ------------------
            terminate each Project Agreement separately, in accordance with
            Article 17, if (a) a milestone defined in the Project Agreement is
            not achieved, or (b) the Customer

----------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       15
<PAGE>

          for the Project Agreement terminates the program, or (c) the
          Sublicensee terminates its license.

9.3  Material Breach.
     ---------------

     In the event that either Party commits a material breach of any obligations
     under this MCA and such Party fails to (a) remedy that breach within [***]
     after receiving written notice thereof from the non-breaching Party, (b) to
     commence dispute resolution under Article 12 within [***] after receiving
     written notice thereof from the non-breaching Party, then the non-breaching
     Party shall begin dispute resolution under Article 12.  Material Breach
     includes failure to make any payments when due under this CA or any Project
     Agreement.  Nevertheless, failure to pay under one Project Agreement or
     this MCA is not a breach of any other Project Agreement.

9.4  Effect of Termination; Accrued Obligations.
     ------------------------------------------

     Termination of this MCA or each Project Agreement for any reason shall not
     release any Party hereto from any liability which, at the time of such
     termination, has already accrued to the other Party or which is
     attributable to a period prior to such termination, nor preclude either
     Party from pursuing any rights and remedies it may have hereunder or at law
     or in equity which accrued or are based upon any event occurring prior to
     such termination.  All Confidential Information of the other Party shall be
     returned immediately at termination.

9.5  Surviving Provisions.
     --------------------

     On termination of this MCA: the obligations of confidentiality set forth in
     Sections 5.1 and 5.2 shall survive for the time stated therein; export
     control compliance set forth in Section 11.13 shall survive; the
     indemnification obligations set forth in Article 11 and Third Party
     infringement claims set forth in Section 7.7 shall survive as to all claims
     or actions arising from events which occurred before termination.  Article
     12 shall survive termination of this MCA so long as any disputes arising
     prior to such termination exist.  Section 7.1 of this MCA shall survive the
     expiration or termination of this MCA for any reason.

              Article 10.  PRODUCT LIABILITY AND INDEMNIFICATION

10.1  Indemnification Under the MCA -
      ------------------------------

     Neither Party shall indemnify the other Party nor its Affiliates, or
     respective officers, directors, employees and agents and its respective
     successors, heirs and assigns ("Indemnitees"), except for its respective
     gross negligence, for any actions or product liability concerning any
     Licensed Product.  This paragraph does not limit either Party's other
     remedies available to it under the law with respect to Licensed Products.
     TDCC shall provide for product liability indemnification for Licensed
     Products from all its Sublicensees.

10.2  Procedure.
      ---------
     10.2.1  A Party that intends to claim indemnification under this Article 10
             (the "Indemnitee") shall promptly notify the other Party (the
             "Indemnitor") in writing of any loss, claim, damage, liability or
             action in respect of which the Indemnitee or any of its Affiliates
             or their directors, officers, employees, agents, consultants or
             counsel intend to claim such indemnification, and the Indemnitor
             shall have the

----------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       16
<PAGE>

             right to participate in, and, to the extent the Indemnitor so
             desires, to assume the defense thereof with counsel of its own
             choice.

     10.2.2  The indemnity agreement in this Article 10 shall not apply to
             amounts paid in settlement of any loss, claim, damage, liability or
             action if such settlement is made without the consent of the
             Indemnitor, which consent shall not be withheld unreasonably.  The
             failure to deliver written notice to the Indemnitor within a
             reasonable time after the commencement of any such action, if
             prejudicial to its ability to defend such action, shall relieve
             such Indemnitor of any liability to the Indemnitee under this
             Article 10.

     10.2.3  At the Indemnitor's request, the Indemnitee under this Article 10,
             and its employees and agents, shall cooperate fully with the
             Indemnitor and its legal representatives in the investigation and
             defense of any action, claim or liability covered by this
             indemnification and provide full information with respect thereto.

                 Article 11.  EXPORT AND COMPLIANCE WITH LAWS

11.1  The Export Administration Regulations of the United States Department of
      Commerce (EAR) prohibit, except under an individual validated license, the
      exportation from the United States of technical data relating to certain
      commodities (listed in the Export Administration Regulations), unless TDCC
      or its Sublicensee has received certain written assurances from the
      foreign importer.  TDCC hereby agrees to comply with the EAR and shall
      provide that any Sublicensee shall also promise to comply.

11.2  If DIVERSA exports technical data, Enzymes or Licensed Enzymes it hereby
      agrees to comply with the EAR.

11.3  TDCC agrees to obtain, or shall have its Sublicensee obtain, all necessary
      clearances from any government in the Territory for export or re-export
      with respect to Licensed Products.

11.4  This MCA, including all Project Agreements, shall be subject to all the
      United States government, State and local laws and regulations now or
      hereafter applicable to the subject matter of this MCA. Both Parties agree
      to comply with all of these applicable laws.

                        Article 12.  DISPUTE RESOLUTION

12.1  Choice of Law - This MCA and all Project Agreements shall be governed by
      -------------
      the laws of the State of Delaware, excepting its conflict of laws
      principles, in all respects of validity, construction and performance,
      except that all questions concerning the construction, validity, coverage
      or infringement of DIVERSA Patent Rights or Joint Patent Rights shall be
      decided in accordance with the patent law of the country where the patent
      was granted.

12.2  Disputes - Both Parties shall make good faith efforts to resolve any
      --------
      questions concerning construction and performance under this MCA and all
      Project Agreements, excluding DIVERSA Patent Rights and antitrust issues
      (which are settled by court proceeding in the concerned country), by:

     12.2.1  Notice, contact and negotiation, all proceedings and documents in
             English, between the Parties listed under Article 17.1 within one
             hundred twenty (120)

                                       17
<PAGE>

             days from the date of the notice by negotiation either by telephone
             or by meeting in Denver, CO; and

     12.2.2  If unsuccessful under Article 12.2.1, then senior executive
             management with settlement authority and counsel of TDCC and
             DIVERSA shall meet at a mutually agreeable neutral location within
             sixty (60) days from a date of notice that Article 12.2.1 failed to
             resolve the issues. Counsel shall present the legal and factual
             arguments to such executives in English, with supporting evidence
             if necessary, and resolution by these executives is expected within
             ten (10) business days therefrom , which may be reduced to writing
             in English as an amendment to this MCA; and

     12.2.3  If such executives have not met or resolved the issues under
             Article 12.2.2, then within seventy five (75) days from the date of
             the notice under Article 12.2.1, the Parties shall submit the
             issues to mediation in Chicago, IL, in English, in accordance with
             the Rules of the American Arbitration Association ("AAA"), which
             may be modified by the Parties, and judgment shall be binding. The
             Parties agree that the following procedures shall be adhered to
             even though they may, in part, not be in full conformance with said
             Rules:

             (a) Three Mediators shall be selected from a list of at least 20
                 arbitrators selected by the AAA composed of counsel with
                 chemistry, molecular biology, chiral chemistry or
                 pharmaceutical expertise who are practicing or retired partners
                 in law firms or in-house corporate counsel not affiliated with
                 the Parties with at least 15 years of experience in law and
                 knowledge of the pertinent laws of any country relevant to the
                 dispute. If the dispute issue is relevant for a commercial
                 expert to advise the Mediators, one expert selected by the
                 mediators may be used. The mediation proceedings and reports
                 shall be in English. The time from the beginning of submission
                 for mediation and conclusion of any oral or written proceedings
                 shall not exceed six (6) months; and

            (b)  Limited discovery to only that which each Party has a
                 substantial, demonstrable need, and shall be conducted in the
                 most expeditious and cost-effective manner. The Mediators shall
                 resolve any issues with regard to the discovery. Decision by
                 the Mediators shall be given in writing within thirty (30) days
                 from the end of oral proceedings; and

            (c)  The decision by the Mediators is binding, but should either
                 Party then need to have a Court of competent jurisdiction for
                 the Parties enforce the decision, either Party may introduce
                 into court the decision reached by Mediation with its
                 supporting evidence.

                  Article 13.  REPRESENTATIONS AND WARRANTIES

13.1  Organization - Each Party states that it is a corporation duly organized,
      ------------
      validly existing and is in good standing under the laws of the
      jurisdiction of its incorporation or organization, is qualified to do
      business and in good standing as a foreign corporation in each
      jurisdiction in which the performance of its obligations hereunder
      requires such qualification and has all requisite power and authority,
      corporate or otherwise, to conduct its business as now being conducted, to
      own, lease and operate its properties and to execute, deliver and perform
      this MCA and all Project Agreements.

13.2  Authorization - The execution, delivery and performance by it of this MCA
      -------------
      and all Project Agreements have been duly authorized by all necessary
      corporate action and

                                       18
<PAGE>

      do not and will not: (a) require any consent or approval of its
      stockholders or (b) violate any provision of any law, rule, regulation,
      order, writ, judgment, injunction, decree, determination or award
      presently in effect having applicability to it or any provision of its
      charter documents.

13.3  Binding Agreement - This MCA is a legal, valid and binding obligation of
      -----------------
      it, enforceable against it in accordance with its terms and conditions.
      Each Project Agreement shall also be a legal, valid and binding obligation
      of it, enforceable against it in accordance with its respective terms and
      conditions.

13.4  Warranty Disclaimer - EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS MCA,
      -------------------
      NEITHER Party MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, EXPRESS OR
      IMPLIED, WITH RESPECT TO ANY Confidential Information, DIVERSA Patent
      Rights, Know-How, Licensed Enzymes, Licensed Products, Intermediates, APIs
      OR OTHER TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT MATTER OF
      THIS MCA AND HEREBY DISCLAIMS ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR
      A PARTICULAR PURPOSE, NON-INFRINGEMENT, OR VALIDITY OF TECHNOLOGY OR
      PATENT CLAIMS, ISSUED OR PENDING, WITH RESPECT TO ANY AND ALL OF THE
      FOREGOING.

13.5  Limited Liability - EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER DIVERSA
      -----------------
      NOR TDCC WILL BE LIABLE TO THE OTHER Party WITH RESPECT TO ANY SUBJECT
      MATTER OF THIS MCA UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR
      OTHER LEGAL OR EQUITABLE THEORY FOR (a) ANY SPECIAL, INDIRECT, INCIDENTAL,
      CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS OR (b) COST OF
      PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR SERVICES.

                            Article 14.  BANKRUPTCY

14.1  DIVERSA Bankruptcy - If DIVERSA files for protection under bankruptcy
      ------------------
      laws, makes an assignment for the benefit of creditors, appoints or
      suffers appointment of a receiver or trustee over its property, files a
      voluntary petition under any bankruptcy or insolvency act or has any such
      petition filed against it which is not discharged within sixty (60) days
      of the filing thereof, then the rights and licenses granted under or
      pursuant to this MCA shall be deemed to be, for purposes of Section 365(n)
      of the US Bankruptcy Code (11 U.S.C.), licenses or rights to "intellectual
      property" as defined under Section 101(52) of the US Bankruptcy Code.
      DIVERSA agrees that TDCC, as a licensee of such rights under this MCA,
      shall retain and may fully exercise all of its rights and elections under
      the US Bankruptcy Code, subject to performance by the licensee of its
      preexisting obligations under this MCA.

14.2  TDCC Bankruptcy - If TDCC files for protection under bankruptcy laws,
      ---------------
      makes an assignment for the benefit of creditors, appoints or suffers
      appointment of a receiver or trustee over its property, files a voluntary
      petition under any bankruptcy or insolvency act or has any such petition
      filed against it which is not discharged within sixty (60) days of the
      filing thereof, then the rights and licenses granted under or pursuant to
      this MCA shall be deemed to be, for purposes of Section 365(c) and (e)(2)
      of the US Bankruptcy Code (11 U.S.C.), licenses or rights to "intellectual
      property" as defined under Section 101(52) of the US Bankruptcy Code. TDCC
      agrees that DIVERSA, as a licensor of such rights under this MCA, shall
      retain and may fully exercise all of its rights and elections under the US
      Bankruptcy Code, including it right to immediately terminate this MCA.
      Notwithstanding the provisions of this Section 14.2, such right of
      termination shall not

                                       19
<PAGE>

      extend to any TDCC Sublicensees providing that those Sublicensees are
      performing in accord with their obligations under this MCA and Sublicensee
      agreement.

                          Article 15.  FORCE MAJEURE

15.1  Neither Party shall be liable to the other Party for failure of or delay
      in performing obligations set forth in this MCA, and neither Party shall
      be deemed in breach of its obligations, if such failure or delay is due to
      natural disasters or any other cause beyond the reasonable control of a
      Party, and notice of such prevention of prevention of performance is
      promptly provided by the non-performing Party in accordance with Section
      17.1. Such excuse shall be continued so long as the condition constituting
      force majeure continues and the non-performing Party takes reasonable
      efforts to remove the condition.

15.2  In event of such force majeure, the Party affected thereby shall use
      reasonable efforts to cure or overcome the same and resume performance of
      its obligations hereunder.

                    Article 16.  ASSIGNMENT AND SUCCESSORS

16.1  The Parties agree this MCA imposes personal obligations on both Parties.
      Neither Party shall assign any rights under this MCA not specifically
      transferable by its terms without the prior written consent of the other
      Party, except that each Party may, without such consent, assign this MCA
      and the rights, obligations and interests of such Party, in whole or in
      part, including one or more of the Project Agreements, to any of its
      Affiliates so long as such Affiliate can perform that Party's obligations.

16.2  If any Change of Control of a Party occurs and an assignment to such
      purchaser or other transferee of all or substantially al of its assets in
      the line of business to which this MCA or any one of the Project
      Agreements pertains, or to any successor corporation resulting from any
      merger or consolidation of such Party with or into another entity, then
      the other Party may immediately terminate this MCA or any of the Project
      Agreements. In the event of any merger or consolidation by a Party into
      another entity, such Party shall promptly notify the other Party in
      writing of such merger or consolidation ad the obligations under this MCA
      shall be maintained and performed by the successor entity unless modified
      in accordance with Section 18.6 or terminated in accordance with Article
      9.

                              Article 17.  NOTICE

17.1  For the purpose of all written communications and notices between the
      Parties under this MCA, any notice shall be shall be sent by overnight
      courier, registered mail, or facsimile to each Party as follows:

                                       20
<PAGE>

     If to DOW:
          The Dow Chemical Company
          [***]

          Attention: [***]

          Telephone:  [***]
          Facsimile:  [***]

        with a copy to:
          The Dow Chemical Company
          [***]
          Attention:  [***]

          Telephone:
          Facsimile:

     To DIVERSA:
          Diversa Corporation
          10665 Sorrento Valley Road
          San Diego, CA 92121

          Attention:  Patrick McCroskey, PhD
                   Sr. Director, Business Development
          Telephone:  858-623-5179
          Facsimile:  858-626-3779

       with a copy to:
          Diversa Corporation
          10665 Sorrento Valley Road
          San Diego, CA 92121

          Attention:  Carolyn Erickson
                   Vice President, Intellectual Property
          Telephone:  858-623-5104
          Facsimile:  858-453-9133

17.2  Either Party may amend its persons to receive notice or supply any other
      address for service by notifying the other Party in writing.

                     Article 18.  MISCELLANEOUS PROVISIONS

18.1  Headings - Headings in this MCA are included herein for ease of reference
      --------
      and shall not affect the meaning of the provisions of this MCA, nor shall
      they have any other legal effect.

18.2  Interpretation - The Parties acknowledge and agree that: (a) each Party
      --------------
      and its counsel reviewed and negotiated the terms and provisions of this
      MCA and have contributed to its revision; (b) the rule of construction to
      the effect that any ambiguities are resolved against the drafting Party
      shall not be employed in the interpretation of this MCA; and (c) the terms
      and provisions of this MCA shall be construed fairly as to all Parties
      hereto and not

------------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                       21
<PAGE>

      in favor of or against any Party, regardless of which Party
      was generally responsible for the preparation of this MCA.

18.3  Integration, Preclusion Of Prior Understandings - This MCA and its
      -----------------------------------------------
      attachments, including all Project Agreements, represents the entire
      understanding between the Parties with respect to the Field, and
      supersedes all other agreements, express or implied, between the Parties.

18.4  Applicable Law - This MCA shall be construed in accordance with the laws
      --------------
      of the United States if a federal issue, or the laws of the State of
      Delaware if a state issue, as interpreted by the courts in the State of
      Delaware, without regard to choice of law provisions of such laws.

18.5  Severability -
      ------------
     18.5.1  The Parties agree that if any part, term, or provision of this MCA
             shall be found illegal or in conflict with or unenforceable under
             any valid controlling body of law, the validity of the remaining
             provisions shall not be affected thereby.

     18.5.2  In the event the legality of any provision of this MCA is brought
             into question because of a decision by a court of competent
             jurisdiction of any country in which this MCA applies, TDCC, by
             written notice to DIVERSA in accordance with Article 17, may revise
             the provision in question or may delete it entirely so as to comply
             with the decision of said court.

18.6  Alteration - A provision of this MCA may be altered only by a writing
      ----------
      signed by both Parties, except as provided in Section 12.5. A provision of
      this MCA may be altered for a specific Project Agreement by the terms of
      that Project Agreement.

18.7  Waiver, Cumulative Remedies - The waiver by either Party of any term or
      ---------------------------
      condition of this MCA in any one instance shall not be deemed construed to
      be a waiver of such term or condition for any similar instance in the
      future or of any subsequent breach hereof.  Such waiver may be effected
      only by a written document signed by the waiving Party.  All rights,
      remedies, undertakings, obligations and agreements contained in this MCA
      shall be cumulative and none of them shall be a limitation of any other
      remedy, right, undertaking, obligation or agreement of either Party.

18.8  Registration And Recordation -
      -----------------------------
      18.8.1  Each Party agrees to execute such additional papers or documents
              in customary legal form and to make such governmental filings or
              applications as may be necessary or desirable to effect the
              Purpose of this MCA and carry out its provisions. Examples of such
              documents are material transfer agreements and confidentiality
              agreements with a Third Party.

     18.8.2  If the terms of this MCA are such as to require or make it
             appropriate that this MCA or any part of it, or any Project
             Agreement hereto, be registered with or reported to a national or
             supranational agency of any area in which TDCC or its Sublicensee
             will do business under this MCA, TDCC or its Sublicensee shall
             undertake such registration or report at its expense. Prompt notice
             and appropriate verification of the act of registration or report
             of any agency ruling resulting from it will be supplied by TDCC to
             DIVERSA.

18.9  Publicity -
      ---------
      18.9.1  Neither Party shall make the financial terms of this MCA public,
              except as required by law or by mutual consent. Either Party may
              make such disclosure of the existence of this MCA to its
              attorneys, advisors, investors, prospective investors, lenders and
              other financing sources, under circumstances that

                                       22
<PAGE>

              reasonably ensure confidentiality. In the event that a filing of a
              copy of this MCA with the US Securities and Exchange Commission is
              required, then DIVERSA and TDCC shall seek confidential treatment
              of information considered confidential by either Party and shall
              redact the financial and as much other information a possible.

      18.9.2  Any press release or publicity of this MCA shall be reviewed and
              approved by both Parties prior to any release. It is expected that
              a Q&A outline for use in responding to inquires about this MCA
              shall be prepared and used by both Parties. Thereafter both
              Parties may disclose the information contained in such press
              release and Q&A outline without the need for further approval. In
              no event shall the financial terms of this MCA be publicly
              disclosed, except as noted in Sections 12.8.2 and 12.9.1.

18.10  No Agency or Partnership - Nothing contained in this MCA shall give
       ------------------------
       either Party the right to bind the other Party, or be deemed to
       constitute either Party as an agent for the other Party or as a partner
       with the other Party or any Third Party. Nevertheless both Parties may
       represent to a Third Party that they are collaborating together for the
       Field without any agency or partnership implied.

IN WITNESS WHEREOF, each of the Parties hereto has caused this MCA to be
executed in duplicate originals by its duly authorized officers or
representatives on the dates set forth below.  This MCA may be signed in
separate counterparts by facsimile with original signatures bearing the same
date as the facsimile provided promptly thereafter.  The Parties expect that
this MCA will depend upon execution of at least one Project Agreement having the
same Effective Date as this MCA and other Project Agreements thereafter.  This
MCA shall be void ab initio if not signed by both Parties within [***].

Diversa Corporation                         The Dow Chemical Company

/s/ Jay M. Short                            [***]
_____________________________               ____________________________________
Jay M. Short, PhD                           [***]
Chief Executive Officer

Date: _______________________               Date: ______________________________

  .  [***]

                                       23
                                      [***]
-----------------------------
* CONFIDENTIAL TREATMENT REQUESTED<PAGE>

                                                                   EXHIBIT 10.41

CONFIDENTIAL TREATMENT REQUESTED
UNDER 17 C.F.R. (S)(S) 200.80(b) (4), 200.83 AND 240.24b-2

                               PROJECT AGREEMENT

                                    BETWEEN

                            THE DOW CHEMICAL COMPANY

                                      AND

                              DIVERSA CORPORATION
<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------------------
              ARTICLE                             TITLE                                    PAGE
--------------------------------------------------------------------------------------------------------------------
<C>                                   <S>                                     <C>
                1                              Definitions                                   2
--------------------------------------------------------------------------------------------------------------------
                2                              R&D Program                                   5
--------------------------------------------------------------------------------------------------------------------
                3                            Grant of Rights                                 10
--------------------------------------------------------------------------------------------------------------------
                4                                Payments                                    12
--------------------------------------------------------------------------------------------------------------------
                5                       License; Development Reports                         14
--------------------------------------------------------------------------------------------------------------------
                6                         Confidential Information                           15
--------------------------------------------------------------------------------------------------------------------
                7                       Intellectual Property Rights                         17
--------------------------------------------------------------------------------------------------------------------
                8                     Provisions Concerning The Filing,                      18
                                      Prosecution And Maintenance Of
                                             Patent Rights
--------------------------------------------------------------------------------------------------------------------
                9                              Legal Action                                  19
--------------------------------------------------------------------------------------------------------------------
                10                     Termination And Disengagement                         22
--------------------------------------------------------------------------------------------------------------------
                11                     Representations And Warranties                        23
--------------------------------------------------------------------------------------------------------------------
                12                           Indemnification                                 24
--------------------------------------------------------------------------------------------------------------------
                13                         Dispute Resolution                                25
--------------------------------------------------------------------------------------------------------------------
                14                            Miscellaneous                                  25
--------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
----------------------------------------------------------------------------
              APPENDIX                                TITLE
----------------------------------------------------------------------------
<S>                                   <C>
                A-1                     Schedule of DIVERSA Patent Rights
                                      developed under this Project Agreement
----------------------------------------------------------------------------
                A-2                     Schedule of background DIVERSA Patent
                                          Rights (predating this Project
                                       Agreement but needed for the Project
                                                      Field)
----------------------------------------------------------------------------
                B-1                      Schedule of TDCC Patent Rights
                                      developed under this Project Agreement
----------------------------------------------------------------------------
                B-2                     Schedule of background TDCC Patent
                                          Rights (predating this Project
                                       Agreement but needed for the Project
                                                      Field)
----------------------------------------------------------------------------
                 C                      List of Licensed Enzyme and Project
                                                      Field
----------------------------------------------------------------------------
                D-1                            MTA for an Institute
----------------------------------------------------------------------------
                D-2                         MTA for a Toll Manufacturer
----------------------------------------------------------------------------
                D-3                             MTA for a Customer
----------------------------------------------------------------------------
                 E                                  Work Plans
----------------------------------------------------------------------------
                 F                      Schedule of Licensed Patents from
                                      DIVERSA Patent Rights for a Licensed
                                     Product (subset of all of Appendix A-1)
----------------------------------------------------------------------------
                 G                       Intellectual Property Chart
----------------------------------------------------------------------------
                 H                      Project Field Classification for
                                                Milestone Payments
----------------------------------------------------------------------------
</TABLE>
<PAGE>

                               TABLE OF CONTENTS

<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------------------
              EXHIBIT                                 TITLE                                   SOURCE
--------------------------------------------------------------------------------------------------------------------
<C>                                   <S>                                     <C>
                1                                      CDA                        Copy attached to MCA as Exhibit 1
--------------------------------------------------------------------------------------------------------------------
                2                                      MCA                        Copy attached to this Project
                                                                                            Agreement
--------------------------------------------------------------------------------------------------------------------
                3                                 License Template               Attached to this Project Agreement
--------------------------------------------------------------------------------------------------------------------
</TABLE>
<PAGE>

                               PROJECT AGREEMENT

This Project Agreement (including the Appendices and Exhibits hereto, the
"Agreement") by and between THE DOW CHEMICAL COMPANY, a corporation duly formed
and existing under the laws of Delaware, having a place of business at 2030 Dow
Center, Midland, Michigan 48674, United States of America ("TDCC" or a "Party"),
and DIVERSA CORPORATION, a corporation duly formed and existing under the laws
of Delaware, having a place of business at 4955 Directors Place, San Diego,
California 92121, United States of America ("DIVERSA" or a "Party"), is made and
entered into as of the Effective Date.

                                R E C I T A L S

A.   DIVERSA has discovered and developed enzymes and has expertise in the
     rearrangement of DNA to produce and discover genes utilizing proprietary
     technologies for the rapid discovery, development and optimization of
     enzymes. TDCC has a contract manufacturing business for preparing
     pharmaceutical products for the pharmaceutical industry.

B.   TDCC and DIVERSA have entered into a Master Collaboration Agreement,
     effective September 1, 2000, ("MCA") for the discovery, development,
     manufacture, marketing and sale of Licensed Products, Intermediates and API
     products and services for [***].

C.   TDCC and DIVERSA wish to enter into this Agreement in order to perform
     research for the Project Agreements contemplated in the MCA. These
     molecules may be further developed as intermediates/products by TDCC.

D.   DIVERSA will perform research on projects funded and supported by TDCC in
     order to [***].

E.   DIVERSA represents that it has Patent Rights and Know-How that pertain to
     this Agreement.

F.   TDCC is desirous of obtaining, and DIVERSA wishes to grant, a worldwide
     license to [***].

G.   TDCC will perform research to [***] discovered by DIVERSA and/or TDCC.

H.   TDCC and DIVERSA intend to provide an integrated, full-service offering of
     Licensed Enzymes, integrated chemical and biological processing
     capabilities and [***] Licensed Products to Customers.  This service and
     Licensed Products may be offered as early as [***].  This Agreement is a
     portion of the effort to meet this intent of the Parties.

NOW, THEREFORE, in consideration of the mutual covenants contained herein, and
for other good and valuable consideration, the receipt and sufficiency of which
the Parties hereby acknowledge, the Parties hereby agree as follows:

                            Article 1.  DEFINITIONS

When used in this Agreement, the following terms shall have the meanings set out
below, unless the context requires otherwise.  The singular shall be interpreted
as including the plural and vice versa, unless the context clearly indicates
otherwise.

1.1  "Affiliate" means the same as in the MCA.
      ---------

                                      -1-
<PAGE>

1.2   "Agreement Term" means the period beginning on the Effective Date and
      --------------
      ending on the date that is [***] months from the expiration or termination
      of the Research Term or the date that this Agreement is otherwise
      terminated as provided herein.

1.3   "API" means the same as in the MCA.
       ---

1.4   "CDA" means the same as in the MCA, and a copy of which is attached hereto
       ---
      as Exhibit 1.

1.5   "Change of Control" means the same as in the MCA, but, for purposes of
       -----------------
      this Agreement and as part of such definition, Field shall also include
      this Project Field.

1.6   "Confidential Information" means tangible materials that are not
       ------------------------
      commercially available in the form supplied to the other Party and also as
      defined in the MCA.

1.7   "Consultant" means a non-Affiliate person who is under confidentiality to
       ----------
      and paid by a Party to act or advise on that Party's behalf under this
      Agreement.

1.8   "Controls" or "Controlled" means, with respect to intellectual property,
       --------      ----------
      possession (other than by virtue of this Agreement or the MCA) of the
      ability to grant licenses or sublicenses to the other Party hereto or to
      its Sublicensee without violating the terms of any agreement or other
      arrangement with any Third Party and to the knowledge and belief of the
      granting Party without violating the rights of a Third Party.

1.9   "Customers" means the same as in the MCA.
       ---------

1.10  "DIVERSA" means Diversa Corporation, having a place of business at San
       -------
      Diego, California.

1.11  "DIVERSA Know-How" means the same as in the MCA.
       ----------------

1.12  "DIVERSA Intellectual Property" means DIVERSA Patent Rights and DIVERSA
       -----------------------------
      Know-How and Joint Patent Rights.

1.13  "DIVERSA Patent Rights" means the same as in the MCA.  All patents and
       ---------------------
      patent applications subject to this definition are listed on Appendix A-1
      or A-2 or will be included on Appendix A-1 or A-2 attached to this
      Agreement by the expiration of the Research Term.  When a Licensed Product
      is designated, then a subset of these DIVERSA Patent Rights relevant to
      that Licensed Product shall be listed on Appendix F, which listing shall
      be included in a resulting License, if any.

1.14  "DIVERSA Research Results" means Research Results invented or discovered
       ------------------------
      solely by, or on behalf of, DIVERSA.

1.15  "Effective Date" means September 1, 2000.
       --------------

1.16  "Enzyme" means [***].
       ------

1.17  "FTE" means the same as in the MCA.
       ---
1.18  "Intermediate" means the same as in the MCA.
       ------------

1.19  "Jointly Developed or Jointly Invented" means if the item developed or
       -------------------------------------
      invented results from efforts between each Parties' employees or
      Consultants under this Agreement such that (a) Joint Know-How or Joint
      Research Results occurs or (b) a patentable invention occurs, such
      invention is jointly developed or invented if both Parties' employees or
      Consultants are considered inventors under 35 U.S.C. et seq. and 37 C.F.R.
      et seq., as interpreted by the U.S. Patent and Trademark Office and the
      United States Federal Courts.

1.20  "Joint Intellectual Property" means Joint Patent Rights and Joint Know-
       ---------------------------
      How.

-----------------------------
     * CONFIDENTIAL TREATMENT REQUESTED

                                      -2-
<PAGE>

1.21  "Joint Know-How" means know-how that is Jointly Developed or Jointly
       --------------
      Invented.

1.22  "Joint Patent Rights" means patent rights that are Jointly Developed or
       -------------------
      Jointed Invented by both Parties in the course of the performance of this
      Agreement and if both Parties' employees or Consultants are considered
      inventors under 35 U.S.C. et seq. and 37 C.F.R. et seq., as interpreted by
      the U.S. Patent and Trademark Office and the United States Federal Courts.

1.23  "Joint Research Results" means Research Results that are Jointly Developed
       ----------------------
      or Jointly Invented.

1.24  "License" means a license agreement for a Licensed Enzyme in a Project
       -------
      Field between TDCC and DIVERSA resulting from work under this Agreement.
      With respect to each Project Field, such License shall be signed, [***]
      and may include DIVERSA Patent Rights, TDCC Patent Rights and Joint Patent
      Rights that are licensed in accord with the [***]. There may be more than
      one License under this Agreement. A template for this License shall be
      attached hereto as Exhibit 3, within ninety (90) days from the Signature
      Date, and made a part hereof.

1.25  "Licensed Enzyme" means any Enzyme that is developed under this Agreement
       ---------------
      and then commercialized for use in a Project Field. The Licensed Enzyme
      and Project Field shall be designated on and listed in Appendix C attached
      thereto and made a part thereof.

1.26  "Licensed Product" means (a) any product containing or consisting of a
       ----------------
      Licensed Enzyme or (b) any process for making an [***].

1.27  "Licensed Patents" means the same as in the MCA.  These Licensed Patents
       ----------------
      shall be determined for license in accord with the Intellectual Property
      Chart in Appendix G.

1.28  "Material" means the original, tangible materials, other than Enzymes,
       --------
      provided by TDCC or DIVERSA to the other Party in order that the recipient
      Party can perform its obligations under the R&D Program and any samples
      developed during the R&D Program that are exchanged by the Parties.

1.29  "MCA" means the Master Collaboration Agreement between the Parties,
       ---
      effective September 1, 2000, a copy of which is attached hereto as Exhibit
      2.  All references in this Agreement to any portion of or attachments to
      the MCA are incorporated herein by reference.

1.30  "MTA" means a material transfer agreement for exchange of any Licensed
       ---
      Enzyme (with or without DIVERSA Know-How or TDCC Know-How) to any Third
      Party by DIVERSA or TDCC, a copy of which is attached hereto as Appendix D
      for transfer between TDCC or DIVERSA and a Third Party. Appendix D-1 is
      for an Institute; Appendix D-2 is for a Toll Manufacturer; and Appendix D-
      3 is for a Customer. Any MTA shall be used only under the terms of this
      Agreement. Any information concerning Enzymes, Licensed Enzymes or
      Materials transferred between TDCC and DIVERSA that would be deemed
      Confidential Information hereunder (i.e., information provided under the
      confidentiality provisions of this Agreement) shall not require a MTA.

1.31  "Patent Rights" means the same as in the MCA.
       -------------

1.32  "Project Field" means a specific application area within the discovery,
       -------------
      development, manufacture, marketing and sale of Licensed Products and
      services for [***].

1.33  "Project Manager" means a commercial person and/or a research person
       ---------------
      designated by each Party to monitor and direct the Work Plans and terms of
      performance under this Agreement.

1.34  "Purpose" means the same as in the MCA.
       -------

1.35  "R&D Program" means the research and development program to be conducted
       -----------
      during the Research Term by DIVERSA and TDCC pursuant to Article 2 hereof,
      as more fully described in the Work Plans.

1.36  "Research Data" means all data, sequences and any other information
       -------------
      obtained or developed in the course of performance of the R&D Program.

1.37  "Research Results" means Research Data, Enzymes and Materials.
       ----------------

                                      -3-
<PAGE>

1.38  "Research Term" means the period commencing on the Effective Date and,
       -------------
      unless extended by written agreement of the Parties or sooner terminated
      as provided herein, terminating on the [***] anniversary of the Effective
      Date as determined by the Work Plan.

1.39  "Responsible Party" shall have the meaning set forth in Section 8.1.2.
       -----------------

1.40  "Signature Date" means the date of last signature to this Agreement.
       --------------

1.41  "Staffing Level" shall have the meaning set forth in the Work Plans.
       --------------

1.42  "Sublicensee" means the same as in the MCA.
       -----------

1.43  "TDCC" means The Dow Chemical Company, having a place of business at
       ----
      Midland, Michigan.

1.44  "TDCC Intellectual Property" means TDCC Patent Rights and TDCC Know-How
       --------------------------
      and Joint Patent Rights.

1.45  "TDCC Know-How" means the same as in the MCA.
       -------------

1.46  "TDCC Patent Rights" means the same as in the MCA.  All patents and patent
       ------------------
      applications subject to this definition are listed on Appendix B-1 or B-2
      or will be included on Appendix B-1 or B-2 attached to this Agreement by
      the expiration of the Research Term.

1.47  "Territory" means the same as in the MCA.
       ---------

1.48  "Third Party" means the same as in the MCA.
       -----------

1.49  "Work Plans" mean the written plans drafted, presented, and approved by
       ----------
      the Project Managers defining the activities to be carried out for, and
      the budget for, each project within the Project Field during the R&D
      Program, as more specifically detailed [***].

1.50  "Work Plan Decision Date" means a key decision point date indicated in a
       -----------------------
      Work Plan for each Project Field where the Parties will evaluate the
      status of the R&D Program for each such Project Field with respect to the
      current Work Plan Performance Milestone associated with such Project
      Field.

1.51  "Work Plan Performance Milestone" means a specific development objective
       -------------------------------
      as stated for each Project Field in a Work Plan.

                            Article 2.  R&D PROGRAM

2.1  Implementation of the R&D Program.
     ----------------------------------

          2.1.1  Basic Provisions of Program.

               (a)  The primary objective of the R&D Program shall be the
                    identification and development of Enzymes as Licensed
                    Enzymes providing enhanced or new properties useful in the
                    Project Field.

               (b)  DIVERSA and TDCC shall use their reasonable good faith
                    efforts to conduct the research activities set forth in the
                    Work Plans, and to provide Materials and Enzymes as set
                    forth therein. Both Parties shall employ the best methods
                    they know which are legally available to them to perform the
                    Work Plans.

               (c)  In carrying out the R&D Program, in accord with the Work
                    Plans, DIVERSA shall devote such number of FTEs during the
                    Research Term ("Staffing Level") as specified in the Work
                    Plans, as such Work Plans are amended hereunder from time to
                    time, and as set forth herein, and TDCC shall pay DIVERSA
                    for the

---------------------------
     * CONFIDENTIAL TREATMENT REQUESTED

                                      -4-
<PAGE>

                    services of such FTEs as set forth herein. [***]
                    Notwithstanding the foregoing or anything contained herein
                    to the contrary, DIVERSA shall not be obligated to devote
                    more FTEs within any Project Field within the Work Plans
                    than is budgeted and paid for in advance of such Work Plans
                    by TDCC pursuant to Section 4.4.2, regardless of whether the
                    objectives of the Project Field and/or Work Plans are
                    achieved at all or within the periods expected from the Work
                    Plans.

               (d)  DIVERSA and TDCC shall use commercially reasonable efforts
                    to perform the tasks set forth in the Work Plans, and to
                    provide the facilities, materials and equipment necessary to
                    perform the research activities set forth in the Work Plans.

               (e)  DIVERSA and TDCC shall perform all work in accordance with
                    the Work Plans, and if it is deemed necessary by a Party, as
                    mutually agreed upon by the Parties, use the services of a
                    Third Party to achieve the requirements of the Work Plan.
                    DIVERSA or TDCC shall do so at its expense without
                    jeopardizing its obligations under this Agreement.

          2.1.2  Collaborative Efforts and Reports.
                 ---------------------------------

               (a)  The Parties agree that the successful execution of the R&D
                    Program will require the collaborative use of both Parties'
                    areas of expertise. The Parties shall keep the Project
                    Managers fully informed about the status of the portions of
                    the R&D Program they respectively perform. Without limiting
                    the foregoing, each Party shall furnish to the Project
                    Managers semi-annual written reports within 30 days after
                    the end of each calendar quarter, beginning with the quarter
                    ending March 31, 2001 including all work done from the
                    Effective Date, and thereafter by each calendar quarter,
                    describing the progress of its activities in connection with
                    the R&D Program in reasonable detail, including at least:

                    [***]The reports described in this Section 2.1.2 (a) shall
                    describe [***]. All reports and information provided under
                    this Section 2.1.2 (a) shall be deemed Confidential
                    Information of the Party which provided the information.

               (b)  DIVERSA and TDCC shall cooperate in the performance of the
                    R&D Program and, subject to any confidentiality obligations
                    to Third Parties or legal restrictions, shall exchange
                    information and Materials and Enzymes as necessary to carry
                    out the R&D Program pursuant to the provisions of this
                    Agreement. Each Party will attempt to accommodate any
                    reasonable request of the other Party to send or receive
                    personnel for purposes of discussing the R&D Program. Such
                    visits and access will be at mutually agreed times, have
                    defined purposes, be of agreed limited duration, and be
                    scheduled in advance. Each Party shall bear all expenses of
                    their respective personnel related to these visits. It is
                    understood that any such visiting personnel may be subject
                    to reasonable restrictions to protect intellectual property
                    outside the R&D Program and the rights of Third Parties,
                    which may include sequestration from research projects
                    outside of the R&D Program. All personnel shall abide by the
                    required rules for any Third Party visiting that Party's
                    site, including, but not limited to, security, safety,
                    personal injury, alcohol use and other matters.

-----------------------------
     * CONFIDENTIAL TREATMENT REQUESTED

                                      -5-
<PAGE>

               (c)  During the Research Term and for a period required to meet
                    all regulatory requirements, DIVERSA and TDCC shall maintain
                    records of the R&D Program (or cause such records to be
                    maintained) in sufficient detail and good scientific manner
                    as will properly reflect all work done in the R&D Program
                    and results achieved in the performance of the R&D Program.
                    Each Party shall allow the other Party to have reasonable
                    access to all pertinent Research Data generated by or on
                    behalf of such Party with respect to each Licensed Enzyme.
                    This retention of records may be extended if there is a
                    legal proceeding pending (i.e., court action, or U.S.
                    interference or opposition involving the Party's
                    Intellectual Property) where those records are reasonably
                    required and a written request with the reason is provided
                    to the Party. Each Party shall disclose to the other Party
                    such Confidential Information to enable patent protection
                    for the Enzymes and Licensed Enzymes to be obtained. Should
                    Trade Secrets be concerned, the Parties shall discuss the
                    best protection for the Licensed Product.

     2.1.3  Work Plans.
            ----------

               (a)  The Work Plans intended to implement the R&D Program are
                    attached hereto as Appendix E. The Work Plans set forth
                    specific, jointly-defined research activities with respect
                    to [***]. At each [***] with respect to a particular
                    Project Field, the Parties will [***] and determine [***].

                    [***]

                    [***]

                    [***]

               (b)  Subject to Section 4.4, TDCC shall have the right to [***].
                    Further, subject to approval by DIVERSA, which may be given
                    or withheld in DIVERSA's sole and absolute discretion, but
                    shall be given good faith consideration, TDCC shall have
                    the right to [***]. It is understood that the [***] may
                    result in [***]. If [***] is not [***] by its corresponding
                    [***], it is understood that this decision may result in
                    reduction [***] with respect to such Project Field after
                    [***].

               (c)  The Work Plans may be modified by the Parties as described
                    herein, provided that a written copy of each revised Work
                    Plan, which clearly shows such proposed modifications, is
                    agreed to in writing by each of the Project Managers and
                    signed by the Parties, which shall be supplied to each
                    Party as an amendment to Appendix E. If the Parties are
                    unable to agree as to the modification terms of a Work
                    Plan, then the matter shall be addressed as provided in
                    Article 13 below. Notwithstanding the above, TDCC shall be
                    responsible for all FTE payments as described in Section
                    4.4.

               (d)  [***] shall be clearly identified for transfer to TDCC
                    under the terms of this Agreement, which permits TDCC to
                    obtain possession of these Materials, Enzymes and Licensed
                    Enzymes, subject to the terms of this Agreement.

     2.1.4  Disclosures.
            -----------

            If DIVERSA or TDCC wishes to disclose any Research Results to a
            Third Party on a confidential basis (not for publication), it shall
            first submit a description of the proposed disclosure directly to
            all Project Managers for review at least [***] prior to any such
            disclosure. Within [***] of receipt of such description, the Project
            Managers shall notify DIVERSA or TDCC, as the case may be, of their
            approval or denial of such disclosure, provided such approval shall
            not be unreasonably withheld. Failure to provide such notice within
            the [***] period shall be deemed to be consent to the proposed
            disclosure.

                                      -6-
--------------------------
* CONFIDENTIAL TREATMENT REQUESTED

<PAGE>

            Notwithstanding the foregoing, DIVERSA may provide [***] under
            confidentiality terms at least as strict as this Agreement to a
            Third Party without the consent of the Project Managers or TDCC for
            use [***]. DIVERSA shall not [***]. TDCC may provide any Licensed
            Enzyme using the applicable MTA of Appendix D, to any Third Party
            without the consent of the Project Managers or DIVERSA if used
            within the Project Field; provided, however, that [***].

          2.1.5  Project Field Termination.
                 -------------------------

                 In the event that research activities for a Project Field
                 defined in the Work Plans are terminated or suspended as
                 provided for in this Agreement, TDCC agrees [***].  Further,
                 TDCC agrees [***].  If the Parties [***], then the matter shall
                 be addressed as provided in Article 13 below.

2.2  Functions of the Project Managers.
     ---------------------------------

     2.2.1  TDCC and DIVERSA hereby agree to establish Project Managers that
            will act on behalf of both Parties to develop, plan, coordinate,
            supervise and direct the research work defined in the Work Plans.
            The Project Managers shall act in an advisory capacity to the
            Parties. Responsibilities of the Project Managers shall include, but
            shall not be limited to, the following:

          (i)    Role to the Parties.  When advising the Parties, the research
                 -------------------
                 Project Managers shall, among other things, [***]. The
                 commercial Project Manager shall [***].  For any given Party
                 there may be one or two Project Manager(s) to fill these
                 objectives.

          (ii)   Design and Development of Work Plans.  The Project Managers
                 ------------------------------------
                 shall take into account the desires and directions of the
                 Parties on the Work Plans undertaken pursuant to this
                 Agreement. The design and development of the Work Plans by the
                 Project Managers will be based on, but not limited to, [***].

          (iii)  Determination of Licensed Enzyme and License.  The Project
                 Managers shall notify both Parties when an Enzyme shall be
                 designated as a Licensed Enzyme and that a License should be
                 negotiated in accord with Exhibit 3.

     2.2.2  Project Managers for TDCC and DIVERSA.
            -------------------------------------
            TDCC and DIVERSA each shall appoint, in its sole discretion, one
            commercial Project Manager and one Research Project Manager for this
            Agreement. The Project Managers may differ for different Work Plans.
            [***] when a new Project Manager is appointed by a Party in
            substitution of a current Project Manager or as an addition for a
            different Work Plan, each Party shall promptly notify the other
            Party of their Project Managers in accord with Section 14.1.

     2.2.3  Meetings.
            --------
            The Project Managers shall meet, as necessary and in the Project
            Managers' discretion, to develop, plan, coordinate and communicate
            the status of the research work defined in the Work Plans. The
            meetings shall be held at places and on dates selected by the
            Project Managers. The Project Managers may participate in any such
            meeting in person, by telephone or by videoconference. Other
            representatives of the Parties or Consultants shall be permitted to
            participate in these meetings with the prior consent of all of the
            Project Managers.

________________________
     * CONFIDENTIAL TREATMENT REQUESTED

                                      -7-
<PAGE>

     2.2.4  Minutes.
            -------
            The Project Managers shall keep minutes of their meetings that
            record all decisions and all actions recommended or taken. The Party
            not hosting the meeting shall be responsible for the preparation of
            the meeting agenda and shall be responsible for the preparation and
            circulation of the draft minutes. Draft minutes shall be delivered
            by mail, electronic mail or facsimile to each Project Manager within
            [***] after each meeting. Any intellectual property issues that may
            need attention will be highlighted and forwarded to each Party's
            Patent Coordinator. Draft minutes shall be edited by all the Project
            Managers and shall be issued in final form only with their approval
            and agreement as evidenced by their signature on the minutes. A copy
            of the signed minutes shall be retained in each Party's files for at
            least [***] after termination of this Agreement.

     2.2.5  Expenses.
            --------
            DIVERSA and TDCC shall each bear all expenses of their respective
            Project Managers related to their participation and attendance at
            Project Managers meetings.

2.3  Third Party Licenses/Infringement of Third Party Patent Rights.
     --------------------------------------------------------------

     2.3.1  Third Party Licenses. If either Party receives written notice of an
            --------------------
            allegation of possible patent infringement from a Third Party, then
            that Party shall so notify the Patent Coordinators and the Parties.
            The Parties shall resolve the issue, including determining whether
            or not to obtain a Third Party License.

     2.3.2  Third Party Infringement.  If either Party believes that performing
            ------------------------
            a given task in the Work Plans may cause them to infringe a patent
            of a Third Party, that Party may refuse to perform the task and
            suggest an alternative, non-infringing method. The Parties shall be
            informed and decide whether to seek a license.

2.4  Post Research Term Cooperation.
     ------------------------------

     At least three (3) months prior to the expiration of the Research Term, the
     Parties shall meet to agree on mechanisms for coordinating and managing
     activities (including, but not limited to, patent prosecution and
     publication review) that will occur after the expiration of the Research
     Term which would otherwise be addressed by the Project Managers.  Any
     patent applications included in a Party's Intellectual Property or Joint
     Intellectual Property which have not been filed shall be filed in the first
     instance during the Agreement Term, and both Parties shall cooperate with
     respect to all issues and formal papers.  It is expected that if a License
     is signed, it will be in accord with the terms stated in the License
     attached hereto as Exhibit 3, and all patents covering a Party's Patent
     Rights reasonably related to the items to be licensed thereunder shall be
     filed by the signature to the License.  Cooperation for Patent Rights
     issues by the Parties is expected until all patents have issued and any
     extensions of patent term obtained.  It may occur that patents covering
     such Patent Rights will not be filed by the date of execution of the
     License if the Customer desires that the License be signed during a Work
     Plan that is not completed.  In such event, patents covering such Patent
     Rights shall be filed as soon as possible and added to the License.

2.5  [***].

     Each Party hereby agrees [***]; provided that the obligations set forth in
     this sentence with respect to a [***] shall [***], except that [***].

-----------------------
     * CONFIDENTIAL TREATMENT REQUESTED

                                      -8-
<PAGE>

                          Article 3.  GRANT OF RIGHTS

3.1  To TDCC.
     -------

     3.1.1  Subject to the terms and conditions of this Agreement and the MCA,
            DIVERSA hereby grants to TDCC [***]. Additionally, DIVERSA grants
            TDCC [***]. Notwithstanding this provision, TDCC may [***]. TDCC
            must [***] before [***].

     3.1.2  When an Enzyme is designated as a Licensed Enzyme, then [***].

3.2  To DIVERSA.
---  ----------

     3.2.1  Subject to the terms and conditions of this Agreement and the MCA,
            TDCC hereby grants to DIVERSA [***].

     3.2.2  TDCC shall grant DIVERSA [***].

3.3  Assignment.
     ----------

     3.3.1  TDCC.
            ----

            TDCC shall [***].

     3.3.2  DIVERSA.
            -------

            DIVERSA shall [***].

3.4  Retained Rights.
     ----------------

     3.4.1  DIVERSA.
            -------

            (a)  DIVERSA shall retain all right, title and interest in and to
                 [***].

            (b)  DIVERSA may [***].

            (c)  Notwithstanding the license granted to TDCC in Section 3.1,
                 DIVERSA shall [***].

     3.4.2  TDCC.
            ----

            TDCC shall retain all right, title and interest in and to [***].

     3.4.3  Joint Patent Rights.
            -------------------
            The rights to the Joint Intellectual Property shall be in accord
            with the Intellectual Property Chart in Appendix G.

                             Article 4.  PAYMENTS

4.1  Technology Development.
     ----------------------

     [***]

4.2  Exclusivity Fees.
     ----------------

     [***]

4.3  Payments.
     --------

     All payments under Sections 4.1 and 4.2 shall be in accord with the MCA.
     All payments due under this Agreement shall be made in accord with the
     respective sections of Article 4 by bank wire transfer in immediately
     available funds to a bank account designated in writing to TDCC by

---------------------
     * CONFIDENTIAL TREATMENT REQUESTED

                                      -9-
<PAGE>

     DIVERSA. In the event that the due date of any payment subject to this
     Article 4 hereof is a Saturday, Sunday or national holiday, such payment
     may be paid on the following business day. Any late payments shall bear
     interest to the extent permitted by applicable law at the prime rate (as
     reported by the Bank of America, San Francisco, California, or its
     successor), on the date such payment is due plus an additional [***],
     calculated on the number of days such payment is delinquent. The rights
     provided in this Section 4.3 shall in no way limit any other remedies
     available to DIVERSA hereunder.

4.4  FTE Payments.
     ------------

     4.4.1  In addition to the other payments due pursuant to this Article 4,
            TDCC shall pay to DIVERSA:

            (a)  a noncontingent and nonrefundable amount of [***] per FTE for
                 all FTEs for the Project Field as specified in the Work Plans
                 from the Effective Date [***]; and

            (b)  for [***] a noncontingent and nonrefundable amount per FTE
                 equal to DIVERSA's then applicable FTE rate ("Standard FTE
                 Rate") in effect on [***].

            (c)  It is expressly agreed by the Parties that [***]. Unless agreed
                 to in writing by DIVERSA, which agreement may be given or
                 withheld in DIVERSA's sole and absolute discretion, TDCC will
                 [***]. Therefore, [***]. So long as the FTE commitment stated
                 in this Section 4.4 is paid, TDCC [***].

            (d)  Notwithstanding Section 2.1.1(c), [***].

            (e)  It is further understood that the Standard FTE Rate is
                 scheduled to increase to [***] beginning [***], which shall
                 only go into effect for TDCC after [***]. DIVERSA agrees that
                 [***]. If the Parties mutually agree to extend [***] for a
                 Project Field, then the FTE rate in effect prior to that
                 extension shall continue to apply until [***].

     4.4.2  Payments due pursuant to the above Section 4.4.1 shall be made in
            advance, on or before the first day of each calendar quarter, with
            the first and last payments prorated in the event that the Effective
            Date is not the first day of a calendar quarter. Should payment be
            due on a Saturday, Sunday or national holiday, such payment may be
            paid on the following business day. In the event that the Parties
            agree to a different Staffing Level for any given calendar quarter,
            the payment set forth in this Section 4.4 shall be prorated
            accordingly based on the Standard FTE Rate then applicable. Any
            change in the amount of the FTE payment due in a quarter shall be
            reported to TDCC by DIVERSA in writing [***]. Notwithstanding the
            foregoing, within [***]following the Signature Date, TDCC shall pay
            to DIVERSA a noncontingent and nonrefundable amount of [***].

4.5  Milestone Payments
     ------------------

     With respect to each Project Field, TDCC shall pay DIVERSA on the first
     occurrence of the following events:

     (a)  New Product:  A fixed sum in US dollars upon [***]; or
          -----------                                         --

     (b)  Existing Commercial Product: A fixed sum in US dollars upon [***].
          ---------------------------

     For each Project Field in the Work Plans, Appendix H shall define whether
the Project Field is a New Product or an Existing Commercial Product and the
corresponding amount of each milestone payment under this Section 4.5. The
amount of each milestone payment hereunder shall be determined prior to DIVERSA
completing its commitment under a Project Field as defined in the Work Plans.
The amount of each milestone payment shall be added as an amendment to

---------------------------
     * CONFIDENTIAL TREATMENT REQUESTED

                                      -10-
<PAGE>

Appendix H. Notwithstanding anything to the contrary contained herein, (i)
TDCC's rights hereunder to license an Enzyme with respect to a Project Field
corresponding to an Existing Commercial Product shall be subject to TDCC's
payment to DIVERSA of the applicable milestone under this Section 4.5 and (ii)
any License of an Enzyme with respect to a Project Field corresponding to a New
Product shall expressly provide for the payment of the milestone specified in
this Section 4.5.  [***].

                   Article 5.  LICENSE; DEVELOPMENT REPORTS

5.1  License.
     -------

     Subject to Section 4.5, the Parties have agreed to enter into a License to
     [***].   DIVERSA hereby represents:

          (a)  that it is willing and able to grant to TDCC [***], and
          (b)  that to the best of its knowledge, [***].

     With respect to each Project Field, TDCC shall [***].  If TDCC fails to
     e[***], then [***].  The [***] day time period can only be extended by
     mutual written consent of the Parties.

5.2  Retained Rights by TDCC.
     ------------------------

     TDCC may [***], provided [***].  If TDCC desires that a Third Party assist
     TDCC in such research, it shall be in accordance with Sections 3.1, 3.3 and
     3.4.

5.2  Reports.
     -------

     Additionally, where legally possible, each Party shall  inform the other
     Party of the Customers and Sublicensees that are interested in the Licensed
     Enzymes and Project Field.

                      Article 6. CONFIDENTIAL INFORMATION

6.1  Confidentiality.
     ---------------

     6.1.1  General.
            -------

            (a)   DIVERSA and TDCC each recognize that the other Party's
                  Confidential Information constitutes highly valuable and
                  proprietary confidential information. Subject to the terms and
                  conditions of Article 8, DIVERSA and TDCC agree that, except
                  as required by applicable law, rule or regulation (including
                  the filing and prosecution of patent applications) or judicial
                  or administrative order, during the Agreement Term and for
                  five (5) years thereafter, unless these terms are modified by
                  the License, after the expiration of the Agreement Term:

                    (i) each Party will keep confidential and will cause its
                    employees, consultants, and Affiliates, to keep
                    confidential, all Confidential Information of the other
                    Party that is disclosed to it, or to any of its employees or
                    consultants, under or in connection with this Agreement; and

--------------------------
*    CONFIDENTIAL TREATMENT REQUESTED

                                      -11-
<PAGE>

                    (ii)   neither Party nor any of its respective employees,
                    consultants or Affiliates shall use Confidential Information
                    of the other Party for any purpose whatsoever, except as
                    expressly permitted in this Agreement.

          (b) Notwithstanding subsection (a) above:

                    (i)    either Party may disclose the other Party's
                    Confidential Information to the extent reasonably necessary
                    in prosecuting or defending litigation, complying with
                    applicable governmental regulations or court orders or
                    otherwise submitting information to tax or other
                    governmental authorities; provided that, if a Party is
                    required to make any such disclosure of the other Party's
                    Confidential Information, it will give reasonable advance
                    notice to the other Party of such disclosure and will use
                    reasonable efforts to secure confidential treatment of such
                    Confidential Information (whether through protective orders
                    or otherwise); and

                    (ii)   the Parties will reasonably cooperate with each other
                    in the making of reasonable disclosures of Confidential
                    Information to actual and potential agents, investment
                    bankers, investors and potential investors of each Party;
                    provided, however, that such disclosures shall be critically
                    required for an investment objective, notice shall be
                    provided to the Party who owns the Confidential Information
                    to protect its rights, and disclosure shall only be made
                    under the terms of a confidentiality agreement providing
                    protections no less stringent than those contained herein.

     6.1.2  Restricted Access.
            -----------------

            (a) Disclosure of a Party's Confidential Information to any of the
                officers, employees, Consultants or agents of the other Party
                shall be made only if and to the extent necessary to carry out
                rights and responsibilities under this Agreement, shall be
                limited to the maximum extent possible, consistent with such
                rights and responsibilities, and shall only be made to persons
                who are bound to maintain the confidentiality thereof and who
                agree not to use such Confidential Information except as
                expressly permitted by this Agreement. If TDCC discloses any
                DIVERSA Confidential Information to TDCC's Affiliates, it shall
                do so under these same terms and conditions of this Section
                6.1.2.

            (b) Each Party shall use at least the same standard of care, but no
                less than a reasonable standard of care for this industry, as it
                uses to protect its own Confidential Information to ensure that
                its Affiliates, employees, agents, Consultants and other
                representatives do not disclose or make any unauthorized use of
                Confidential Information of the other Party. Each Party shall
                promptly notify the other Party of any unauthorized use or
                disclosure of Confidential Information of the other Party.

            (c) Within [***] following termination or expiration of this
                Agreement Term, each Party will return to the other Party, or
                destroy, upon the written request of the other Party, all
                Confidential Information disclosed to it by the other Party
                pursuant to this Agreement, including all copies and extracts of
                documents; provided that a Party may retain Confidential
                Information of the other Party relating to any License or right
                to use Licensed Patent Rights that survives such termination,
                and one copy of all other Confidential Information may be
                retained in confidential and inactive archives

--------------------
*    CONFIDENTIAL TREATEMNT REQUESTED

                                      -12-
<PAGE>

                solely for the purpose of establishing the contents thereof and
                to determine the continuing obligations of each Party.

     6.1.3  Employee Confidentiality Agreements.
            -----------------------------------

            DIVERSA and TDCC each represent that all of its employees and any
            Consultants participating in the R&D Program or who shall otherwise
            have access to Confidential Information of the other Party are bound
            by written agreements to maintain such information in confidence and
            not to use such information except as expressly permitted herein.
            Each Party agrees to enforce confidentiality obligations by which
            its employees and Consultants are bound.

6.2  Publicity.
     ---------

     Except as expressly provided herein, neither Party may disclose the
     existence or terms of this Agreement without the prior written consent of
     the other Party; provided, however, that either Party may make such
     disclosure to the extent required by law and that either Party may make a
     disclosure of the existence of this Agreement to its attorneys, advisers,
     investors, prospective investors, lenders and other financing sources,
     under circumstances that reasonably ensure the confidentiality thereof.

     Notwithstanding the foregoing, the Parties shall mutually agree upon:

     (a)  A press release to announce the execution of this Agreement which
          includes mutually agreed upon financial terms, such as funding and
          sharing terms, together with a corresponding Q&A outline for use in
          responding to inquiries about the Agreement; thereafter, TDCC and
          DIVERSA may each disclose to Third Parties the information contained
          in such press release and Q&A outline without the need for further
          approval by the other Party. Either Party may disclose information
          regarding this Agreement to the extent required by any Securities and
          Exchange Commission filings or regulations, but all financial terms
          must be redacted prior to submission.

     (b)  In addition, DIVERSA may (i) make public statements regarding Licensed
          Enzymes by announcing in general terms [***], following consultation
          with TDCC and with the prior written consent of TDCC, and (ii) without
          the prior consent of TDCC, make public statements, without identifying
          TDCC, [***].

     (c)  Subject to the applicable terms of the MCA and this Agreement, if any,
          governing disclosures related to Licensed Enzymes, TDCC is free to
          make public statements, press releases, and the like, with respect to
          Licensed Enzymes and Licensed Products.

6.3  Publication.
     -----------

     A Party wishing to publish or otherwise publicly disclose its Research
     Results shall first submit a draft of the proposed manuscripts
     simultaneously to all Project Managers for review by the other Party at
     least [***] prior to any submission for publication or other public
     disclosure.  To avoid loss of patent rights as a result of premature public
     disclosure of patentable information, the reviewing Party shall notify the
     submitting Party in writing within [***] after receipt of such proposed
     disclosure whether the reviewing Party desires that a patent application be
     filed on any invention disclosed in such proposed disclosure.  In the event
     that the reviewing Party desires such filing, the submitting Party shall
     withhold publication or disclosure of such proposed disclosure until the
     earlier of (i) the date a patent application is filed thereon, or (ii) the
     date the Parties determine after consultation that no patentable invention
     exists, or (iii) [***] after receipt by the submitting Party of the
     reviewing Party's written notice of the reviewing Party's desire to file
     such patent application.  If the proposed disclosure contains Confidential
     Information of the reviewing Party that is subject to nondisclosure
     obligations under this Article 6, the submitting Party agrees to remove
     such Confidential Information upon request of the reviewing Party.

                                      -13-
----------------------------
* CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

                   Article 7.  INTELLECTUAL PROPERTY RIGHTS

7.1  Disclosure of Inventions.
     ------------------------

     Each Party shall promptly inform the Project Managers of all Research
     Results relevant to the progress of the Work Plans towards its pre-agreed
     goals.

7.2  Ownership.
     ---------

     All intellectual property rights, which are in possession of either Party
     as of the Effective Date, shall remain in the possession of that Party.
     Ownership of inventions conceived of during the course of the collaboration
     in the Project Field will be as follows:

     7.2.1  DIVERSA Intellectual Property Rights.
            ------------------------------------

            DIVERSA shall have sole and exclusive ownership of all right, title
            and interest on a worldwide basis in and to [***].

     7.2.2  TDCC Intellectual Property Rights.
            ---------------------------------

            TDCC shall have sole and exclusive ownership of all right, title and
            interest on a worldwide basis in and to [***].

     7.2.3  Joint Intellectual Property Rights.
            ----------------------------------

            TDCC and DIVERSA shall jointly own all Joint Research Results.

     7.2.4  Inventions Relating to Licensed Enzymes or Licensed Products.
            -------------------------------------------------------------

            Notwithstanding the foregoing, the Parties shall own their
            respective patent rights for Licensed Products and Licensed Patent
            Rights as agreed to by the Parties at the time an Enzyme becomes a
            Licensed Enzyme. As of the date hereof, the Parties agree that
            [***].

     7.2.5  Trade Secrets.
            -------------
            If any Trade Secrets are developed, they shall remain the property
            of the Party that developed it. Such Trade Secrets may not be
            disclosed to the other Party.

7.3  Patent Coordinators.
     -------------------

     DIVERSA and TDCC shall each appoint a patent coordinator ("Patent
     Coordinator") who shall serve as such Party's primary liaison with the
     other Party on matters relating to ownership of Inventions, inventorship,
     patent filing, prosecution, maintenance and enforcement.  Each Party may
     replace its Patent Coordinator at any time by written notice in writing to
     the other Party.  The initial Patent Coordinator from DIVERSA is [***] and
     from TDCC is [***].

7.4  Inventorship.
     ------------

     Except as specifically provided above, ownership of Inventions and
     inventorship shall be determined by the Patent Coordinators in accordance
     with United States patent law and using the[***], subject to Section 7.2.4.
     If the Patent Coordinators can not agree on inventorship or ownership of
     Inventions, then a neutral patent attorney, acceptable to both Parties,
     shall make the determination, with each Party equally sharing the costs.

7.5  Deposits.
     --------

     Should deposits of a Licensed Enzyme be desired by either Party to support
     the filing of a patent application, both Parties agree to cooperate to
     enable and obtain such deposit.  Ownership of and costs for the deposit
     shall be borne by the Party responsible in accordance with Article 8.
     [***]

---------------------------
* CONFIDENTIAL TREATMENT REQUESTED

                                      -14-
<PAGE>

           Article 8.  PROVISIONS CONCERNING THE FILING, PROSECUTION

                        AND MAINTENANCE OF PATENT RIGHTS

     The following provisions relate to the filing, prosecution and maintenance
of Licensed Patent Rights or DIVERSA Patent Rights or TDCC Patent Rights subject
to License rights under this Agreement.

8.1  Filing and Prosecution of Patents.
     ---------------------------------

     8.1.1  Primary Responsibilities.
            ------------------------

            In consultation with the Patent Coordinators, the Project Managers
            will coordinate the determination of what patents will be filed on
            Research Results resulting from the R&D Program. Unless the Project
            Managers agree otherwise in writing, the Parties shall have the
            following responsibilities for patent filing, prosecution and
            maintenance (including the defense of interferences, oppositions and
            similar proceedings) (collectively, "Patent Activities"):

            (a)  TDCC Inventions.  TDCC will be responsible, at its sole
                 ---------------
                 expense, for Patent Activities with respect to Licensed Patent
                 Rights made solely by TDCC.

            (b)  DIVERSA Inventions.  DIVERSA will be responsible, at its sole
                 ------------------
                 expense, for Patent Activities with respect to Inventions made
                 solely by DIVERSA.

            (c)  Joint Intellectual Property.  In the case of Joint Intellectual
                 ---------------------------
                 Property and Joint Patent Rights not otherwise covered in
                 Section 8.1.1, Patent Activities shall be conducted by outside
                 counsel, reasonably acceptable to both Parties, with equal
                 control and joint responsibility for costs incurred in
                 connection with the applicable Patent Activities. The Parties
                 shall be free to agree not to patent Joint Intellectual
                 Property and/or retain such Joint Intellectual Property as a
                 trade secret.

            (d)  Intellectual Property [***]. TDCC and DIVERSA shall make
                 ----------------------
                 reasonable efforts to License the Licensed Patent Rights to the
                 other in accord with [***]. The effort to commercialize
                 Licensed Products should be encouraged and protected to the
                 best extent possible for the Parties to provide for protection
                 for the Customers and Sublicensees.

     8.1.2  Cooperation.
            -----------

            In each case in Section 8.1.1 above, the Party responsible for
            Patent Activities for the applicable patent applications (the
            "Responsible Party") shall use reasonable efforts to obtain patent
            coverage that is as broad as possible to cover all potential
            commercial applications thereof. Each Party shall be kept informed
            of all substantive matters relating to the preparation and
            prosecution of all patent applications under the Joint Patent
            Rights. Additionally, TDCC and DIVERSA agree to confer with regard
            to their patent filing activities under Section 8.1.1 (a) - (c) to
            ensure that concurrent filing of patents and discussion on prior art
            occur and any Joint Inventions are mutually determined and defined
            as to the scope as deemed necessary by the Patent Coordinators.
            Coordinate filing to maximize protection.

8.2  Elective Termination of Rights.
     ------------------------------

     If at any time the Responsible Party does not wish to file any patent
     application or wishes to discontinue the prosecution or maintenance of any
     Patent Rights claiming any Licensed Enzyme

----------------------------------
         * CONFIDENTIAL TREATMENT REQUESTED

                                      -15-
<PAGE>

     or Licensed Product filed in any country, it shall promptly give notice of
     such intention to the other Party. The latter shall have the right, but not
     the obligation, to assume responsibility for the filing, prosecution or
     maintenance of any such Patent Rights on a country-by-country basis at its
     own expense, by giving notice to the Responsible Party of such intention
     within [***]. No assignment of Patent Rights shall be made to the other
     Party unless specifically agreed to under appropriate negotiated terms and
     conditions. In any such case, the Party declining such responsibilities
     shall not grant any Third Party a license under its interest in the
     applicable Patent Rights in the applicable country or countries and may not
     practice the applicable Patent Rights for any commercial use (but may
     practice, royalty free such Patent Rights for research use) without the
     prior written consent of the other Party. The other Party will bear the
     costs of Patent Activities with respect to all Patent Rights for which it
     has assumed responsibility pursuant to this Section 8.2. The Parties may
     elect to publish rather than file for patent protection or may abandon
     filed patent rights by mutual written consent.

                            Article 9.  LEGAL ACTION

9.1  Actual or Threatened Infringement.
     ---------------------------------

     9.1.1  Notice.
            ------

            In the event either Party becomes aware of any actual or threatened
            commercially material infringement or unauthorized possession
            anywhere in the world, knowledge or use of any Patent Rights
            (collectively, an "Infringement"), that Party shall, within [***],
            notify the other Party and provide it with all available details to
            the extent it is legally permitted to do so. The Parties will meet
            to discuss the appropriate course of action, and may collaborate in
            pursuing such course or action.

     9.1.2  Primary Responsibility.
            ----------------------

            (a)  Notwithstanding the foregoing, if the Parties do not otherwise
                 agree on a course of action, TDCC shall have primary
                 responsibility for the prosecution, prevention or termination
                 of any Infringement of TDCC Patent Rights hereunder, at TDCC's
                 expense and with the sharing of recoveries as specified below.

            (b)  DIVERSA shall have primary responsibility for the prosecution,
                 prevention or termination of any Infringement of DIVERSA Patent
                 Rights, at DIVERSA's expense and with the sharing of recoveries
                 as specified below.

            If either Party which has primary responsibility as described in (a)
            or (b) above determines that it is necessary or desirable for the
            other Party to join any such suit, action or proceeding, the other
            Party shall execute all papers and perform such other acts as may be
            reasonably required in the circumstances, at the expense of the
            Party which has primary responsibility.

     9.1.3  Jointly-Owned Patents.
            ---------------------

            In the event of an Infringement of Joint Patent Rights, the Parties
            shall agree which Party will have the rights and responsibilities of
            abating such Infringement, and how the expenses and any recovery
            thereof shall be shared. In this event, the responsible Party shall
            use patent counsel reasonably acceptable to the other Party, and
            shall keep the other Party fully informed as to the status of such
            matters. In the event only one Party wishes to pursue such
            proceeding, it shall have the right to proceed alone, at its
            expense, and may retain any recovery, and the other Party agrees, at
            the request and expense of

-------------------------------
     * CONFIDENTIAL TREATMENT REQUESTED

                                      -16-
<PAGE>

            the Party initiating such action, to cooperate and join in any
            proceedings in the event that a Third Party asserts that the co-
            owner of such Joint Invention is necessary or indispensable to such
            proceedings.

     9.1.4  Costs.
            -----

            TDCC shall bear the cost of any proceeding or suit under this
            Section 9.1 brought by TDCC; and DIVERSA shall bear the cost of any
            such proceeding or suit brought by DIVERSA. In each such case, the
            Responsible Party shall have the right [***].

     9.1.5  Separate Counsel.
            ----------------

            Each Party shall always have the right to be represented by counsel
            of its own selection and at its own expense in any suit instituted
            under this Section 9.1 by the other Party for an Infringement.

     9.1.6  Standing.
            --------

            If either Party lacks standing and the other Party has standing to
            bring any such suit, action or proceeding as specified above, then
            the Responsible Party may request the other Party to do so at the
            Responsible Party's expense. The Party with standing is under no
            obligation to comply with such request, but rather is free to refuse
            such request.

     9.1.7  Cooperation.
            -----------

            In any action under this Section 9.1, each Party shall fully
            cooperate with and assist the other Party as reasonably requested.
            No suit regarding DIVERSA Intellectual Property or Joint
            Intellectual Property may be settled by TDCC without DIVERSA's prior
            written consent. No suit regarding TDCC Intellectual Property or
            Joint Intellectual Property may be settled by DIVERSA without TDCC's
            prior written consent.

9.2  Defense of Claims Asserted by Third Parties Against TDCC.
     --------------------------------------------------------

     TDCC shall defend, indemnify and hold DIVERSA and its Affiliates, and their
     respective agents, directors, officers, and employees harmless from and
     against any and all losses, liabilities, claims, demands, damages, costs,
     expenses or money judgments (including reasonable attorneys' fees and
     expenses) incurred by or rendered against any of them for personal injury,
     sickness, disease or death or property damage which arise out of:
     (a)  the development, manufacturing, testing, handling, storage, use,
          promotion, sale or distribution of Licensed Products by TDCC or its
          Affiliates, except for those instances for which DIVERSA, and not
          TDCC, performs any of these functions; or
     (b)  the breach by TDCC of any of its representations, warranties or
          covenants contained in this Agreement; or
     (c)  the intentional misconduct or gross negligence of TDCC;
     provided, however, that DIVERSA shall give TDCC notice in writing in accord
     with Article 14 as soon as practicable of any such claim or lawsuit and
     shall permit TDCC to undertake the defense thereof at TDCC's expense.
     However,
          (i)  DIVERSA will cooperate in such defense by providing access to
               witnesses and evidence available to it. DIVERSA shall have the
               right, at its expense, to participate in any defense to the
               extent that in its judgment, DIVERSA may be prejudiced thereby;
               and
          (ii) In any claim or suit in which DIVERSA seeks indemnification by
               TDCC, DIVERSA shall not settle, offer to settle or admit
               liability or damages in any such claim or suit without the prior
               written consent of TDCC.

--------------------------------
      * CONFIDENTIAL TREATMENT REQUESTED

                                      -17-
<PAGE>

9.3.  Defense of Claims Asserted by Third Parties Against DIVERSA.
      -----------------------------------------------------------

      DIVERSA shall indemnify and hold TDCC, its agents, directors, officers,
      employees and Affiliates harmless from and against any and all
      liabilities, claims, demands, damages, costs, expenses or money judgments
      (including reasonable attorneys' fees and expenses) incurred by or
      rendered against any of them for personal injury, sickness, disease or
      death or property damage which directly arise out of:
          (a)  the intentional misconduct or negligence of DIVERSA; or
          (b)  the breach by DIVERSA of its representations, warranties or
               covenants contained in this Agreement; or
          (c)  any activity carried out with Enzymes or Licensed Enzyme by
               DIVERSA or its Affiliates other than through TDCC and its
               Affiliates under this Agreement;
      provided, however, that TDCC shall give DIVERSA notice in writing in
      accord with Article 14 as soon as practicable of any such claim or lawsuit
      and shall permit DIVERSA to undertake the defense thereof (including the
      right to settle the claim solely for monetary consideration) at DIVERSA's
      expense. However,
          (i)  TDCC will cooperate in such defense by providing access to
               witnesses and evidence available to it.  TDCC shall have the
               right, at its expense, to participate in any defense to the
               extent that in its judgment, TDCC may be prejudiced thereby; and
          (ii) in any claim or suit in which TDCC seeks indemnification by
               DIVERSA, TDCC shall not settle, offer to settle or admit
               liability or damages in any such claim or suit without the prior
               written consent of DIVERSA.

9.4  Notice.
     ------

     TDCC or DIVERSA shall notify the other in accord with Section 14.1 of any
     suits or claims or proceedings brought against it under Section 9.2 or 9.3,
     respectively.

                   Article 10.  TERMINATION AND DISENGAGEMENT

10.1  Term.
      ----

      The term of this Agreement, together with all Project Fields, will
      commence as of the Effective Date and will continue until the end of the
      Agreement Term. The Parties will commence negotiations [***] prior to the
      end of the Research Term to extend the Agreement Term - if the Work Plan
      requires more time to be completed - on mutually acceptable terms, and
      complete such negotiations prior to the end of the Agreement Term;
      provided, however, that neither Party shall be obligated to extend the
      Agreement Term if mutually acceptable terms are not agreed to prior to the
      end of the Agreement Term. This Agreement may be terminated at any time
      upon mutual written agreement of the Parties or unilaterally by TDCC on
      [***] written notice to DIVERSA, provided that TDCC pays DIVERSA for FTEs
      as specified by the Work Plans (i.e., for all FTEs with respect to each
      Project Field as specified in the Work Plans until [***]) and this
      Agreement. Thus, TDCC may terminate this Agreement in its entirety or
      separately for each Project Field so long as the FTE payment due [***] has
      been met in accord with Section 4.4.

10.2  Change of Control.
      -----------------

      The Parties shall have the right to terminate this Agreement upon the
      occurrence of a Change of Control of either Party during the term of this
      Agreement by providing written notice of termination to the other Party
      within [***] following receipt of written notice of the occurrence of such
      Change of Control. In the event that the Party does not terminate this
      Agreement under this Section 10.2, this Agreement will be binding upon the
      Party subject to the Change of Control, or any successor to such Party.
      Notwithstanding this paragraph, this Agreement may be terminated and all
      Licenses be retained.

                                      -18-
---------------------------
* CONFIDENTIAL TREATMENT REQUESTED
<PAGE>

10.3  Material Breach.
      ---------------

      In the event that a Party commits a material breach of any of its
      obligations under this Agreement, and such Party fails (i) to remedy that
      breach within [***] after receiving written notice thereof from the other
      Party or (ii) to commence dispute resolution under this Agreement within
      [***] after receiving written notice of that breach from the non-breaching
      Party, the non-breaching Party may immediately terminate this Agreement,
      upon written notice to the breaching Party. Notwithstanding any material
      breach of this Agreement, any existing Licenses are to be retained in
      effect, unless terminated under the provisions of each License.

10.4  Breach of Payment Obligations.
      -----------------------------

      In the event that TDCC fails to make timely payment of any amounts due
      under this Agreement, within [***] after demand therefor, DIVERSA may
      terminate this Agreement upon prior written notice, unless TDCC cures such
      breach by paying all past-due amounts, together with all interest accrued
      thereon, if any, within such [***] notice period, provided that TDCC shall
      be entitled to use such cure provision no more than [***] for this
      Agreement.

10.5  Bankruptcy.
      ----------

      10.5.1  If either Party (the "Insolvent Party") files for protection under
              bankruptcy laws, makes an assignment for the benefit of creditors,
              appoints or suffers appointment of a receiver or trustee over its
              property, files a voluntary petition under any bankruptcy or
              insolvency act or has any such petition filed against it which is
              not discharged within of the filing thereof, then the other Party
              may, at its sole election upon notice to the Insolvent Party,
              terminate this Agreement by written notice to such Party.

      10.5.2  All rights and licenses granted under or pursuant to this
              Agreement shall be deemed to be, for purposes of Section 365(n) of
              the U.S. Bankruptcy Code, licenses or rights to "intellectual
              property" as defined under Section 101(52) of the U.S. Bankruptcy
              Code. The Parties agree that each Party, as a licensee of such
              rights under this Agreement, shall retain and may fully exercise
              all of its rights and elections under the U.S. Bankruptcy Code,
              subject to performance by the licensee of its preexisting
              obligations under this Agreement.

10.6  Effect of Termination; Accrued Obligations.
      ------------------------------------------

      10.6.1   Accrued Obligations.
               -------------------

               Termination of this Agreement for any reason shall not release
               any Party hereto from any liability which, at the time of such
               termination, has already accrued to the other Party or which is
               attributable to a period prior to such termination, nor preclude
               either Party from pursuing any rights and remedies it may have
               hereunder or at law or in equity which accrued or are based upon
               any event occurring prior to such termination.

     10.6.2    Licenses.
               ---------

               In the event this Agreement terminates pursuant to this Section
               10, then the R&D Program shall immediately terminate, all
               payments due by TDCC to DIVERSA shall immediately terminate
               except for payments to DIVERSA for DIVERSA FTEs as specified in
               the Work Plans (i.e., for all FTEs with respect to each Project
               Field as specified in the Work Plans until [***]) and this
               Agreement, and the Licenses granted to either Party in Article 3
               shall continue (to provide assurance for the Customers and
               Sublicensees).

--------------------------
     * CONFIDENTIAL TREATMENT REQUESTED

                                      -19-
<PAGE>

10.7  Surviving Provisions after Termination of this Agreement.
      --------------------------------------------------------

      Articles 12 and 14 and Sections 6.1, 6.2, 6.3, 7.2, 7.4, 7.5, 10.5, 11.1.4
      and 11.1.5 of this Agreement and any executed Licenses shall survive the
      expiration or termination of this Agreement for any reason.

                  Article 11.  REPRESENTATIONS AND WARRANTIES

11.1  Mutual Representations.
      ----------------------

     DIVERSA and TDCC each represents and warrants as follows:

     11.1.1   Organization.
              ------------

              It is a corporation duly organized, validly existing and is in
              good standing under the laws of the jurisdiction of its
              incorporation, is qualified to do business and in good standing as
              a foreign corporation in each jurisdiction in which the
              performance of its obligations hereunder requires such
              qualification and has all requisite power and authority, corporate
              or otherwise, to conduct its business as now being conducted, to
              own, lease and operate its properties and to execute, deliver and
              perform this Agreement.

     11.1.2   Authorization.
              -------------

              The execution, delivery and performance by it of this Agreement
              have been duly authorized by all necessary corporate action and do
              not and will not: (a) require any consent or approval of its
              stockholders or (b) violate any provision of any law, rule,
              regulation, order, writ, judgment, injunction, decree,
              determination or award presently in effect having applicability to
              it or any provision of its charter documents.

     11.1.3   Binding Agreement.
              -----------------

              This Agreement is a legal, valid and binding obligation of it,
              enforceable against it in accordance with its terms and
              conditions.

     11.1.4   Warranty Disclaimer.
              -------------------

              The Parties acknowledge that the research activities contemplated
              hereunder are experimental, and that the R&D Program may not be
              successful. EXCEPT AS OTHERWISE EXPRESSLY PROVIDED IN THIS
              Agreement, NEITHER Party MAKES ANY REPRESENTATION OR WARRANTY OF
              ANY KIND, EXPRESS OR IMPLIED, WITH RESPECT TO ANY Confidential
              Information, Patent Rights, DIVERSA Know-How, TDCC Know-How
              Enzymes, Licensed Enzymes, Licensed Products, Intermediates, APIs,
              OR OTHER TECHNOLOGY, GOODS, SERVICES, RIGHTS OR OTHER SUBJECT
              MATTER OF THIS Agreement AND HEREBY DISCLAIMS ANY WARRANTY OF
              MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-
              INFRINGEMENT, OR VALIDITY OF TECHNOLOGY OR PATENT CLAIMS, ISSUED
              OR PENDING, WITH RESPECT TO ANY AND ALL OF THE FOREGOING.

     11.1.5   Limited Liability.
              -----------------

              EXCEPT AS EXPRESSLY PROVIDED HEREIN, NEITHER DIVERSA NOR TDCC WILL
              BE LIABLE TO THE OTHER Party WITH RESPECT TO ANY SUBJECT MATTER OF
              THIS Agreement UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR
              OTHER LEGAL OR EQUITABLE THEORY FOR (i) ANY SPECIAL, INDIRECT,
              INCIDENTAL, CONSEQUENTIAL OR PUNITIVE DAMAGES OR LOST PROFITS OR
              (ii) COST OF PROCUREMENT OF SUBSTITUTE GOODS, TECHNOLOGY OR
              SERVICES.

                                      -20-
<PAGE>

                         Article 12.  INDEMNIFICATION

12.1  Indemnification.
      ----------------

      Neither Party shall indemnify the other Party nor its Affiliates, or
      respective officers, directors, employees and agents and its respective
      successors, heirs and assigns ("Indemnitees") except for Sections 9.2 and
      9.3, its respective gross negligence, or failure to perform using its
      reasonable best efforts under the Work Plans. This paragraph does not
      limit either Party's other remedies available to it under the laws.

12.2  Procedure.
      ---------

      12.2.1  A Party that intends to claim indemnification under this Article
              12 (the "Indemnitee") shall promptly notify the other Party (the
              "Indemnitor") in writing of any loss, claim, damage, liability or
              action in respect of which the Indemnitee or any of its Affiliates
              or their directors, officers, employees, agents, consultants or
              counsel intend to claim such indemnification, and the Indemnitor
              shall have the right to participate in, and, to the extent the
              Indemnitor so desires, to assume the defense thereof with counsel
              of its own choice.

      12.2.2  The indemnity agreement in this Article 12 shall not apply to
              amounts paid in settlement of any loss, claim, damage, liability
              or action if such settlement is made without the consent of the
              Indemnitor, which consent shall not be withheld unreasonably. The
              failure to deliver written notice to the Indemnitor within a
              reasonable time after the commencement of any such action, if
              prejudicial to its ability to defend such action, shall relieve
              such Indemnitor of any liability to the Indemnitee under this
              Article 12.

      12.2.3  At the Indemnitor's request, the Indemnitee under this Article 12,
              and its employees and agents, shall cooperate fully with the
              Indemnitor and its legal representatives in the investigation and
              defense of any action, claim or liability covered by this
              indemnification and provide full information with respect thereto.

                        Article 13.  DISPUTE RESOLUTION

13.1  Informal Dispute Resolution.
      ---------------------------

      The Parties recognize that a bona fide dispute as to certain matters may
      from time to time arise during the Agreement Term, which relates to either
      Party's rights or obligations hereunder. In the event of the occurrence of
      such a dispute, either Party may, by written notice to the other Party,
      have such dispute referred to the Chief Executive Officer of DIVERSA and
      the President in charge of Specialties of TDCC, or their successors or
      counterparts, for resolution by good faith negotiations within [***] after
      such notice is received at a mutually convenient location or by telephonic
      or video conferencing.

      If the dispute is not resolved by the good faith efforts under the above
      paragraph, then either Party may terminate this Agreement, but not
      Licenses, in accord with Article 10.

                           Article 14.  MISCELLANEOUS

14.1  Notices.
      -------

      All notices (including, but not limited to legal matters) shall be in
      writing mailed via certified mail, return receipt requested, or overnight
      express mail, courier providing evidence of delivery, addressed as
      follows, or to such other address as may be designated by notice so given
      from time to time:

                                      -21-
<PAGE>

<TABLE>
<CAPTION>
                <C>                   <S>
                If to TDCC:           THE DOW CHEMICAL COMPANY
                                      [***]
                                      Midland, Michigan 48674
                                      Attention:  [***]

                If to DIVERSA:        DIVERSA CORPORATION
                                      4955 Directors Place
                                      San Diego, California   92121
                                      Attention:  Patrick McCroskey
</TABLE>

If the notice relates to scientific matters, such as a Work Plan, or a project,
the notice for the Parties is to be supplied and received in the manner
described above but sent to:

<TABLE>
<CAPTION>
<C>                                             <S>
If to TDCC:                                     THE DOW CHEMICAL COMPANY
                                                [***]
                                                Midland, Michigan 48674
                                                Attention:  [***]

If to DIVERSA:                                  DIVERSA CORPORATION.
                                                4955 Directors Place
                                                San Diego, California   92121
                                                Attention:  Mary Perez
</TABLE>

Notices shall be deemed given as of the date received. Any Party may change its
designated address or contact person by notice to the other Party in the manner
provided in this Section.

14.2 Governing Law and Jurisdiction.
     ------------------------------

     This Agreement shall be governed by and construed in accordance with the
     laws of the State of [***], without regard to the application of principles
     of conflicts of law.

14.3 Binding Effect.
     --------------

     This Agreement shall be binding upon and inure to the benefit of the
     Parties and their respective legal representatives, successors and
     permitted assigns.

14.4 Headings.
     --------

     Section and subsection headings are inserted for convenience of reference
     only and do not form a part of this Agreement.

14.5 Counterparts.
     ------------

---------------------------
   * CONFIDENTIAL TREATMENT REQUESTED

                                      -22-
<PAGE>

      This Agreement may be executed simultaneously in two or more counterparts,
      each of which shall be deemed an original.

14.6  Amendment; Waiver.
      -----------------

      This Agreement may be amended, modified, superseded or canceled, and any
      of the terms may be waived, only by a written instrument executed by each
      Party or, in the case of waiver, by the Party or Parties waiving
      compliance. Nevertheless, Appendices C and D may be amended by the
      signatures of both Patent Coordinators listed in Section 7.3. The delay or
      failure of any Party at any time or times to require performance of any
      provisions shall in no manner affect the rights at a later time to enforce
      the same. No waiver by any Party of any condition or of the breach of any
      term contained in this Agreement, whether by conduct, or otherwise, in any
      one or more instances, shall be deemed to be, or considered as, a further
      or continuing waiver of any such condition or of the breach of such term
      or any other term of this Agreement.

14.7  No Agency or Partnership.
      ------------------------

      Nothing contained in this Agreement shall give either Party the right to
      bind the other Party, or be deemed to constitute either Party as an agent
      for the other Party or as a partner with the other Party or any Third
      Party.

14.8  Assignment and Successors.
      -------------------------

      Except as expressly provided herein, this Agreement may not be assigned by
      either Party without the prior written consent of the other Party, except
      that each Party may, without such consent, assign this Agreement and the
      rights, obligations and interests of such Party, in whole or in part, to
      any of its Affiliates in accord with Section 3.3, to any purchaser or
      other transferee of all or substantially all of its assets in the line of
      business to which this Agreement pertains, or to any successor corporation
      resulting from any merger or consolidation of such Party with or into
      another entity, subject, however, in the case of DIVERSA to the
      restriction set forth in Section 3.3.2. In the event of any merger or
      consolidation by a Party into another entity, such Party shall promptly
      notify the other Party in writing of such merger or consolidation and the
      obligations under this Agreement shall be maintained and performed by the
      successor entity unless modified in accord with Section 14.6.

14.9  Force Majeure.
      -------------

      Neither TDCC nor DIVERSA shall be liable to the other Party for failure of
      or delay in performing obligations set forth in this Agreement, and
      neither shall be deemed in breach of its obligations, if such failure or
      delay is due to natural disasters or any other cause beyond the reasonable
      control of a Party, and notice of such prevention of performance is
      promptly provided by the non-performing Party to the other Party. Such
      excuse shall be continued so long as the condition constituting force
      majeure continues and the non-performing Party takes reasonable efforts to
      remove the condition. In event of such force majeure, the Party affected
      thereby shall use reasonable efforts to cure or overcome the same and
      resume performance of its obligations hereunder.

14.10 Interpretation.
      --------------

      The Parties hereto acknowledge and agree that: (i) each Party and its
      counsel reviewed and negotiated the terms and provisions of this Agreement
      and have contributed to its revision; (ii) the rule of construction to the
      effect that any ambiguities are resolved against the drafting Party shall
      not be employed in the interpretation of this Agreement; and (iii) the
      terms and provisions of this Agreement shall be construed fairly as to all
      Parties hereto and not in a favor of or against any Party, regardless of
      which Party was generally responsible for the preparation of this
      Agreement.

14.11 Integration: Severability.
      -------------------------

      This Agreement (including the Appendices and Exhibits attached hereto) and
      the MCA set forth all of the agreements and understandings between the
      Parties with respect to the subject matter of

                                      -23-
<PAGE>

        this Agreement and supersede all other agreements and understandings
        between the Parties with respect to the same.

        If any provision of this Agreement is or becomes invalid or is ruled
        invalid by any court of competent jurisdiction or is deemed
        unenforceable, it is the intention of the Parties that the remainder of
        this Agreement shall not be affected. If possible, the invalid provision
        shall be replaced with a valid provision, which meets the intent of the
        Parties.

14.12   Approvals.
        ---------

        14.12.1 TDCC shall be responsible, at its expense, for obtaining any
                approvals from governmental entities which may be required under
                applicable law for the development of Licensed Products, and
                shall use its best efforts to obtain all necessary approvals as
                soon as reasonable.

        14.12.2 DIVERSA shall be responsible, at its expense, for obtaining any
                approvals from governmental entities which may be required under
                applicable law for the shipment of Licensed Enzymes to TDCC to
                perform its obligations under the R&D Program.

14.13   Export Controls.
        ---------------

        This Agreement is made subject to any restrictions concerning the export
        of Licensed Products, Research Results or either Party's Intellectual
        Property (collectively, "Technology") from the United States that may be
        imposed upon either Party from time to time by laws or regulations of
        the United States. Neither Party will export, directly or indirectly,
        any Technology to any country for which the United States government or
        any agency thereof at the time of export requires an export license or
        other governmental approval, without first obtaining the written consent
        to do so from the Department of Commerce, Bureau of Export
        Administration, or other agency of the United States government when
        required by applicable statute or regulation.

                                      -24-
<PAGE>

     IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed
in duplicate originals, or in separate counterparts, and/or by facsimile as of
the last signature date below, by their duly authorized representatives.

                                         THE DOW CHEMICAL COMPANY

Date:   11/30/00                         By:       [***]
     --------------------------------       ---------------------------------
                                                   [***]

                                         DIVERSA CORPORATION

Date:    11/30/00                        By:       /s/ Jay M. Short
     --------------------------------       ---------------------------------
                                                   Jay M. Short, Ph.D.
                                                   Chief Executive Officer

Appendix Enc.:
--------------
[***]

                                      -25-
                                     [***]
-------------------------------
      * CONFIDENTIAL TREATMENT REQUESTED

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00023-of-00352.parquet"}]]